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Abstract Cell fate decisions occur through the switch-like, irreversible activation of fate-
specifying genes. These activation events are often assumed to be tightly coupled to changes in
upstream transcription factors, but could also be constrained by cis-epigenetic mechanisms at
individual gene loci. Here, we studied the activation of Bcl11b, which controls T-cell fate
commitment. To disentangle cis and trans effects, we generated mice where two Bcl11b copies are
tagged with distinguishable fluorescent proteins. Quantitative live microscopy of progenitors from
these mice revealed that Bcl11b turned on after a stochastic delay averaging multiple days, which
varied not only between cells but also between Bcl11b alleles within the same cell. Genetic
perturbations, together with mathematical modeling, showed that a distal enhancer controls the
rate of epigenetic activation, while a parallel Notch-dependent trans-acting step stimulates
expression from activated loci. These results show that developmental fate transitions can be
controlled by stochastic cis-acting events on individual loci.
DOI: https://doi.org/10.7554/eLife.37851.001
Introduction
During development, individual cells establish and maintain stable gene expression programs
through the irreversible activation of lineage-specifying regulatory genes. A fundamental goal of
developmental biology is to understand how and when these activation events are initiated to drive
cell fate transitions. The concentrations of active transcription factors in the nucleus are crucial for
embryonic patterning and progressive gene expression changes in development (Briscoe and Small,
2015; Davidson, 2010; Jaeger, 2011) and are often assumed to directly dictate rates of target
gene transcription (Coulon et al., 2013; Estrada et al., 2016; Phillips, 2015). At the same time, an
additional layer of epigenetic control mechanisms acts directly at gene loci on chromosomes,
through chemical modification of DNA or DNA-associated histone proteins (Bird, 2002; Tessarz and
Kouzarides, 2014), or regulation of chromosome conformation or packing in the nucleus
(Felsenfeld and Dekker, 2012). Chromatin modification and accessibility changes are ultimately ini-
tiated by the binding and action of trans-acting factors; however, while these changes are often
assumed to closely follow transcription factor changes, other recent work shows that epigenetic pro-
cesses could occur slowly (Kaikkonen et al., 2013; Mayran et al., 2018), and could introduce slow,
stochastic, rate-limiting steps to gene activation, even when transcription factor inputs are fully pres-
ent (Berry et al., 2017; Bintu et al., 2016). Despite much work, it has generally remained unclear
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what role, if any, epigenetic mechanisms play in controlling the timing and outcome of developmen-
tal gene activation and cell fate decisions.
Epigenetic control is ordinarily difficult to disentangle from control due to changes in transcrip-
tion factor activity. However, the two mechanisms can be distinguished by their effects on different
gene copies in the same cell (Bonasio et al., 2010). Control due to transcription factor changes
occurs in trans, and thus affects two copies of the gene in the same cell coordinately; in contrast,
epigenetic mechanisms function at single gene copies, in cis, and thus could generate distinct activa-
tion states for different gene copies in the same cell, a concept that underlies the utility of X-chro-
mosome inactivation and other systems as models for epigenetic gene control (Berry et al., 2015;
Deng et al., 2014; Farago et al., 2012; Gendrel and Heard, 2014; Ku et al., 2015; Xu et al.,
2006). For this reason, tracking both copies of a gene in the same cell with distinguishable fluores-
cent proteins can provide insight into the dynamics of cis and trans regulatory processes
(Elowitz et al., 2002; Yang et al., 2017).
Using this approach of tracking two gene copies, we have studied the developmental activation
of Bcl11b, a key driver of T-cell commitment and identity. To become a T-cell, hematopoietic pro-
genitors transition through a series of developmental states, where they lose alternate lineage
potential and eventually commit to the T-cell lineage (Figure 1A). T-cell lineage commitment
requires the irreversible switch-like activation of Bcl11b, which serves to repress alternate lineage
potential and establish T-lineage identity (Ikawa et al., 2010; Li et al., 2010a; Li et al., 2010b).
Bcl11b is regulated by an ensemble of transcription factors, including Runx1, GATA-3, TCF-1, and
Notch, which bind to multiple locations on the gene locus (Li et al., 2013; Kueh et al., 2016). How-
ever, even when these developmentally controlled transcription factors have been fully mobilized,
Bcl11b activation occurs only after an extended time delay of ~4 days, allowing pre-commitment
expansion of progenitors (Kueh et al., 2016). During activation, the Bcl11b locus remodels its epige-
netic state, undergoing changes in DNA methylation and histone modification (Ji et al., 2010;
Zhang et al., 2012), nuclear positioning, genome compartmentalization and looping interactions
(Hu et al., 2018), and expression of a cis-acting lncRNA transcript (Isoda et al., 2017). These obser-
vations suggest that the dynamics of Bcl11b activation could be determined by epigenetic processes
as well as transcription factors.
To separately follow two Bcl11b copies in developing cells, we engineered a dual-color reporter
mouse, where the two Bcl11b copies are tagged with distinguishable fluorescent proteins. We then
used quantitative live-cell imaging to follow Bcl11b activation dynamics in single progenitor lineages,
along with mathematical modeling and perturbation experiments to dissect the relative contribu-
tions of cis- and trans- acting inputs to Bcl11b regulation. Our results revealed that activation of
Bcl11b and consequent T-cell commitment require a stochastic, cis-acting epigenetic step on the
Bcl11b locus. This step occurs independently at the two alleles in the same cell, with a slow timescale
spanning multiple days and cell cycles. A separate trans-acting step, controlled by the T-cell devel-
opmental signal Notch, occurs in parallel with this cis-acting step and provides an additional neces-
sary input for Bcl11b activation. Finally, we found that over the course of development, T-cell
progenitors lose the ability to activate the cis-epigenetic switch, and as a result, can progress to final
differentiated states with only one Bcl11b locus stably activated. Together, these results show that
intrinsically stochastic events occurring at single gene copies can determine the timing and outcome
of mammalian cell fate decisions.
Results
Two Bcl11b copies show slow, independent activation in single
progenitor lineages
We generated a double knock-in reporter mouse strain, with an mCitrine yellow fluorescent protein
(YFP) inserted non-disruptively in the 3’-untranslated region of one Bcl11b copy and an mCherry red
fluorescent protein (mCh) at the same site in the other copy (Figure 1B and Figure 1—figure sup-
plement 1). Both Bcl11b copies contain a floxed neomycin resistance cassette downstream of the
fluorescent protein (Figure 1—figure supplement 1); however, we have shown conclusively, using
Cre-mediated excision, that this cassette has no effect on Bcl11b activation (Kueh et al., 2016). We
isolated thymocyte populations at different stages of development and differentiation directly from
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dual reporter Bcl11b mice, and measured the fraction of cells expressing Bcl11b from each allele at
stages spanning the initial onset of Bcl11b expression (Figure 1C). As reported previously
(Kueh et al., 2016; Tydell et al., 2007), Bcl11b was inactive in early T-cell progenitors (ETPs), and
began to turn on in the subsequent CD4, CD8 double negative (DN)2a stage, becoming expressed
in all cells throughout the rest of T-cell development (Figure 1A,C,D). By DN2b and DN3 stages, the
large majority of cells had turned on both Bcl11b copies. These transitions involve multiple cell
cycles each, with about 2 days between late ETP and DN2a and about 3 days between DN2a and
DN2b (Kueh et al., 2016). However, in the DN2a compartment where Bcl11b gene activation
begins, a significant fraction of the cells expressed only one copy of Bcl11b, with roughly equal frac-
tions of cells expressing either the YFP or mCherry (mCh) alleles (Figure 1C, arrowheads). This sug-
gested that the two Bcl11b copies could turn on at different times in the same cell during
development.
To determine directly whether two Bcl11b copies switch on independently in the same cell, we
used multi-day timelapse imaging to follow the two Bcl11b fluorescent reporters in clonal lineages
of developing progenitors. We isolated Bcl11b-negative DN2a T-cell progenitors from dual Bcl11b
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Figure 1. Dual-color Bcl11b reporter strategy can reveal epigenetic mechanisms controlling T-cell lineage commitment. (A) Overview of early T-cell
development. Bcl11b turns on to silence alternate fate potentials and drive T-cell fate commitment. ETP – early thymic progenitor; DN2 – CD4-
CD8-double negative-2A progenitor; DP – CD4+ CD8+; NK – natural killer; DC – dendritic cell. (B) Dual-allelic Bcl11b reporter cells, where two
distinguishable fluorescent proteins (YFP and mCherry) are inserted non-disruptively into the same sites on the two endogenous Bcl11b loci. (C) Flow
cytometry plots show cKit versus CD25 levels in CD4-CD8- double negative (DN) thymic progenitors (left), along with Bcl11b-YFP versus Bcl11b-mCh
expression levels in the indicated DN progenitor subsets from dual Bcl11b reporter mice. Arrowheads indicate cells expressing one copy of Bcl11b. (D)
Flow plots show Bcl11b-YFP versus Bcl11b-mCh levels in CD4+CD8+double positive (DP) T-cell precursors from the thymus (left), or CD4 (center) or CD8
(right) T-cells from the spleen. Results are representative of analysis of 6–8 mice from two independent experiments. See also Figure 1—figure
supplement 1.
DOI: https://doi.org/10.7554/eLife.37851.002
The following figure supplement is available for figure 1:
Figure supplement 1. Experimental strategy for generating different Bcl11b reporter mouse strains.
DOI: https://doi.org/10.7554/eLife.37851.003
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reporter mice, transduced them with cyan fluorescent protein (CFP)-expressing retroviral constructs
for cell tracking, and cultured them in vitro at limiting dilution with OP9-DL1 stromal cells
(Schmitt and Zu´n˜iga-Pflu¨cker, 2002), confining them in microwells to allow tracking of descendants
of each progenitor over multiple days (Figure 2A). We used OP9-DL1 cells to present the Notch
ligand DL1, a critical T-cell developmental signal, and included the supportive cytokines Interleukin
(IL) 7 and Flt3 ligand (see Materials and methods). The ~1 hr interval between successive frames did
not permit complete lineage tracking due to rapid cell movement (Video 1), but still enabled map-
ping and visualization of all descendants, and determination of coarse-grained lineage relationships
(Figure 2B,C, bottom left).
We had previously shown that about 3 days are required for half of the cells in such DN2a popula-
tions to turn on any Bcl11b expression (Kueh et al., 2016). In theory, this delay could reflect require-
ment for activation of some additional transcription factor. However, even a novel transcription
factor would be able to work on both alleles in parallel. Instead, strikingly, imaging revealed strongly
asynchronous activation of the two Bcl11b copies in the same cell during this time period. Within sin-
gle clonal lineages from DN2a progenitors, one copy of Bcl11b could switch on multiple days and
cell generations before the other (Figure 2B,C and Video 1), giving rise to distinct allelic expression
states that persisted over multiple divisions. Across clones, however, similar percentages of cells
activated Bcl11b-YFP first as compared to those turning on Bcl11b-mCherry first, consistent with
independent activation (Figure 2D,E). Similar activation rates for both alleles were also observed on
average across populations from individual mice regardless of parent-of-origin (data not shown), rul-
ing out any imprinting-type bias. These results indicated that the allelic bias within clones was clon-
ally inherited.
From a dynamic point of view, we observed that in some clones, the times at which a Bcl11b
allele first turned on differed between progeny of a single cell (Figure 2C, 42 hr), such that individual
progenitors frequently gave rise to clonal descendants with multiple distinct states of Bcl11b allelic
activation (53.3% heterogeneous after 4d, N = 15, Figure 2—figure supplement 1). A substantial
percentage (~40%) of all cells remained mono-allelic in expression after 4d (Figure 2E), indicating
that stochastic locus activation occurs with a slow time constant spanning multiple days. Further-
more, the fractions of cells mono-allelically expressing Bcl11b-YFP or Bcl11b-mCh increased with the
same dynamics, indicating that each locus is triggered with the same stochastic activation rate. We
note that the percentages of mono-allelic cells generated at given timepoints on OP9-DL1 co-culture
differed from those in DN2b progenitors from the thymus, which have emerged from Bcl11b non-
expressing DN2a cells at some unknown time in the past (40% versus ~15%, Figure 1C). This could
reflect differences in the kinetics of Bcl11b allelic activation between the OP9-DL1 system and the
thymic microenvironment. However, in both cases, we observed clearly defined Bcl11b mono-allelic
as well as bi-allelic expressing populations, implying that the same slow cis- event observed in in
vitro tracking experiments also governs Bcl11b activation and T-lineage commitment in the thymus.
Taken together, these results suggest that timing of the Bcl11b activation switch – and the ensuing
commitment to become a T-cell – is controlled independently at each Bcl11b allele by a stochastic
and remarkably slow rate-limiting step.
A distal enhancer modulates stochastic Bcl11b locus activation
The stochastic transition of Bcl11b from an inactive to active state may be controlled by specific cis-
regulatory DNA elements on the Bcl11b locus. Consistent with this idea, we found that graded
changes in Notch signaling, GATA-3 activity, and TCF-1 activity alter the likelihood of all-or-none
activation, rather than the amplitude of transcription (Kueh et al., 2016). Indeed, in a number of sys-
tems, cis-regulatory elements do not appear to control transcriptional amplitudes, but instead mod-
ulate the probabilities of all-or-none activation (Fukaya et al., 2016; Khan et al., 2011;
Walters et al., 1995; Weintraub, 1988). To test how stochastic activation of individual Bcl11b alleles
may be controlled, we examined the effect of disrupting the one known positive cis-regulatory ele-
ment region, which resides ~850 kb downstream of Bcl11b within a ‘super enhancer’ at the opposite
end of the same topologically associated domain (Li et al., 2013) (Figure 3A). This region, which
shows distinctive histone marking and some T-lineage-specific transcription factor occupancy even
before Bcl11b activation (Kueh et al., 2016), lies about 11 kb from the promoter of a Bcl11b-associ-
ated lncRNA, and loops to the Bcl11b gene body in a T-cell lineage specific manner (Hu et al.,
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Research article Computational and Systems Biology Developmental Biology
D) E)
A)
B)
C)
103
104
103
104 103 104 103 104 103 104
Bcl11b-YFP
time (hours)
fr
a
ct
io
n
B
cl
1
1
b
-m
C
h
e
rr
y
5 hr
n
o
rm
a
liz
e
d
fr
e
q
u
e
n
cy
35 hr 65 hr 95 hr
4 hr
1 hr 42 hr 73 hr 96 hr
55 hr 110 hr
YFP
mCh
YFP
mCh
103 104
103
104
105
103
104
105
105
103 104 105
0 50 100
0 50 100
103
105
103
105
103
105
103
105
time (hours) Bcl11b-YFP
time (hours) Bcl11b-YFP
B
cl
1
1
b
-m
C
h
e
rr
y
B
cl
1
1
b
-m
C
h
e
rr
y
B
cl
1
1
b
-m
C
h
B
cl
1
1
b
-Y
F
P
B
cl
1
1
b
-m
C
h
B
cl
1
1
b
-Y
F
P
0
0.5
0
1
40 80 120
yellow
red
both
days
Bcl11b YFP/mCh
expand,
sort DN2
progenitors
120
80
40
0
hrs
120
80
40
0
hrs
single clone
single clone
0
1
4 55
1 42 73 96 (hr)
110 (hr)
ti
m
e
 (
h
o
u
rs
) 1
42
73
96
ti
m
e
 (
h
o
u
rs
) 1
55
110
1 2 3 4 5 6 7 8
2
1
1
3 4 5 6 7 8
2 3
4 5
6 7 8
1 32 4 5 5 6 7 8
Figure 2. Two copies of Bcl11b switch on independently and stochastically in the same cell in single lineages of T-cell progenitors. (A) Bcl11b-negative
DN2 cells derived from bone-marrow progenitors were isolated by flow cytometry, cultured within microwells, and followed for 5 days using
fluorescence imaging. Cells were then segmented using automated image analysis. (B–C). Dynamics of Bcl11b activation in two representative clonal
progenitor lineages. Timelapse images (top) show developing T-cell progenitors from two representative clones (left), with segmented cell boundaries
in white. Numbers (top left) indicate time in hours. Scale bar = 10 microns. Trees (bottom left) show coarse-grained cell lineage relationships for the
cells shown here. Plots (center, lower rows) show Bcl11b-YFP and Bcl11b-mCh expression time traces in all cells from a single clone, with vertical gray
bars indicating the time points of the image shown on the left. Horizontal lines indicate activation threshold. Colored scatterplots (bottom right) show
Figure 2 continued on next page
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2018; Isoda et al., 2017; Li et al., 2013). Like the Bcl11b locus itself, this enhancer region is marked
by H3K27me3 in non-T lineage cells (Li et al., 2013).
Using standard gene targeting, we deleted this distal ~2 kb enhancer region on the Bcl11b-YFP
allele, leaving the Bcl11b-mCherry allele intact, to generate Bcl11bYFPDEnh/mCh dual reporter mice
(Figure 3A and Figure 1—figure supplement 1), and then analyzed resultant effects on YFP regula-
tion in different T-cell subsets (Figure 3B,C and Figure 3—figure supplements 1–3). These were
analyzed either from established young adult Bcl11bYFPDEnh/mCh mice (Figure 3B,C and Figure 3—
figure supplements 1,2) or from adult chimeras populated with fetal liver cells from the F0 genera-
tion (Figure 3—figure supplement 3A,B). The non-disrupted Bcl11b-mCherry allele served as an
internal, same-cell control. At the ETP stage, essentially all Bcl11b alleles were silent, regardless of
whether they had an intact or disrupted enhancer, as expected (Figure 3B). During the DN2a and
DN2b stages, the enhancer-disrupted Bcl11b-YFP allele showed dramatically reduced activation
compared to the Bcl11b-mCherry allele in the
same cell. Interestingly, at later developmental
stages in the thymus and in peripheral T-cell sub-
sets (CD4, Treg, CD8) a large fraction of cells
showed expression of the enhancer-disrupted
YFP allele, along with the wild-type Bcl11b-
mCherry allele (Figure 3B,C and Figure 3—fig-
ure supplements 1,2,3), indicating that the tar-
geted element is not indispensable for Bcl11b
activation. However, a small but significant per-
centage of cells still failed to activate the
enhancer-disrupted allele, and instead persisted
in a mono-allelic state with only expression of
the Bcl11b-mCherry allele (Figure 3B,C and Fig-
ure 3—figure supplements 1,2,3). Mono-allelic
cells were found in memory as well as naı¨ve
T-cell subsets (Figure 3—figure supplement 2),
implying that these mono-allelically expressing
cells are capable of immune responses, as
expected from the normal phenotype of Bcl11b
knockout heterozygotes. As shown in fetal liver
chimeras, generation and persistence of Bcl11b-
mCherry mono-allelic cells due to the mutant
Bcl11bYFPDEnh allele were determined cell intrin-
sically (Figure 3—figure supplement 3). How-
ever, from flow cytometric profiles, cells that
turned on the disrupted allele expressed it at
normal levels, suggesting that the enhancer
mutation reduced the stochastic rate of Bcl11b
Figure 2 continued
time evolution of Bcl11b-mCh versus Bcl11b-YFP levels in single clones, from 0 hr (cyan) to 120 hr (purple). (D) Heat maps show Bcl11b-YFP and Bcl11b-
mCh distributions in the polyclonal population at the indicated time points. White lines represent Bcl11b expression thresholds. Color bar (left)
represents normalized cell numbers at each time point. (E) Fractions of cells having different Bcl11b allelic expression states over time, obtained by
mixed Gaussian fitting of the heat maps shown. Data represent a cohort of ~200 starting cells from a single timelapse movie. Overall, data show that
Bcl11b switches on slowly and stochastically in single lineages of progenitors, maintaining alternate activity states in the same clone, heritable across
many divisions. Results are representative of three independent experiments. See also Figure 2—figure supplement 1 and Video 1.
DOI: https://doi.org/10.7554/eLife.37851.004
The following source data and figure supplement are available for figure 2:
Source data 1. Differential Bcl11b allelic expression states over time for a cohort of ~200 starting cells.
DOI: https://doi.org/10.7554/eLife.37851.006
Figure supplement 1. Bcl11b shows heterogeneity in locus activation within clonal progenitor lineages.
DOI: https://doi.org/10.7554/eLife.37851.005
Video 1. Timelapse movie of a single clonal DN2
progenitor lineage. Bcl11b-YFP-mCh- DN2 progenitors
were cultured on OP9-DL1 monolayers with 5 ng/mL IL-
7 and Flt3-L within individual PDMS micro-wells, and
continuously imaged for 100 hr. Images show
superposition of a DIC image (gray) and cellular
fluorescent intensities from the Bcl11b-mCherry (red)
and Bcl11b-YFP (green) channels, with segmented cell
boundaries shown in white. For clarity, images show
only the fluorescence intensities within the cell
boundaries, excluding auto-fluorescence from well
boundaries and OP9-DL1 monolayers. Scatter-plot
(bottom-right) updates with each frame to show
fluorescent intensities of segmented cells at
corresponding time points. Scale bar = 50 microns.
DOI: https://doi.org/10.7554/eLife.37851.007
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Figure 3. A distal enhancer region controls Bcl11b activation probability. (A) Schematic of normal and enhancer-deleted two-color Bcl11b reporter
strains (left). Genome browser plots (right), showing +850 kb enhancer of Bcl11b, showing distributions of histone marks (H3K4me2, H3K27me3, and
H3K27Ac) and an associated LncRNA (Isoda et al., 2017). Orientation is with transcription from left to right (reversed relative to genome numbering).
Gray shaded area indicates the enhancer region deleted using gene targeting (removed region: chr12:108,396,825–108,398,672, mm9). (B) Flow
Figure 3 continued on next page
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activation, but not its expression level once activated.
To directly test this hypothesis, we measured Bcl11b-YFP activation with or without enhancer dis-
ruption, by sorting DN2 progenitors with zero or one allele activated, culturing on OP9-DL1 feeders,
and analyzing activation dynamics of both alleles using flow cytometry. Consistently, enhancer dis-
ruption greatly reduced the fraction of cells that turned on Bcl11b-YFP, but did not perturb its
expression level in cells that already successfully activated it (Figure 3D). Neither the wildtype nor
the enhancer-disrupted allele reverted to silence after being activated. These results show that the
deleted region within the distal Bcl11b super-enhancer works selectively, in cis, to accelerate the
irreversible stochastic switch of the Bcl11b locus from an inactive to an active state.
The activation of the enhancer-disrupted Bcl11b allele observed in many DN2b and later cells
suggests that there are other cis-regulatory elements on the Bcl11b locus that can also promote sto-
chastic locus activation. The extended intergenic gene desert between Bcl11b and the next gene,
Vrk1, is rich in potential regulatory elements that could compensate for the disruption of the
enhancer element in the cells activating the YFP allele (Hu et al., 2018). Alternatively, the intact
enhancer at the mCherry-tagged locus in the same cell could activate the enhancer-deleted Bcl11b
locus in trans, but this was ruled out when we bred mice with the enhancer disruption to homozygos-
ity (Bcl11bYFPDEnh/YFPDEnh). Progenitors from these mice were still able to turn on Bcl11b and to
undergo T-cell development to CD4, CD8 double positive (DP) and single positive (SP) cells, and all
the cells in these populations had normal levels of Bcl11b expression (Figure 3—figure supplement
4). Thus, the enhancer we identified works together with other regulatory elements specifically to
control Bcl11b activation timing.
Figure 3 continued
cytometry plots show Bcl11b-mCh versus Bcl11b-YFP levels in developing T-cell populations from dual Bcl11b reporter mice, either with an intact YFP
enhancer (top), or a disrupted YFP enhancer (bottom). Results are representative of two independent experiments. (C) Bar graphs showing the
percentages of cells in early thymic populations with mono- and bi-allelic expression of wildtype mCherry and wildtype YFP versus mutant YFP alleles in
wildtype Bcl11bYFP/mCh and Bcl11bYFPDEnh/mCh dual reporter mice, demonstrating the reduced frequency of mutant YFP allele expression relative to the
wildtype mCherry allele in the same cells. Each bar shows results from one mouse; n = 4 mice of each strain are shown. (D) DN2 progenitors were
sorted for different Bcl11b allelic activation states as indicated, cultured on OP9-DL1 monolayers for 4 days, and analyzed using flow cytometry. Flow
plots show Bcl11b-mCh versus Bcl11b-YFP levels of cells generated from precursors with a normal (top) or disrupted (bottom) YFP enhancer, showing
defective YFP up-regulation from the mutant relative to the wildtype alleles. Enhancer disruption reduces the probability of switch-like Bcl11b
activation, but does not affect expression levels after activation. Results are representative of two independent experiments. See also Figure 1—figure
supplement 1, and Figure 3—figure supplement 1–4.
DOI: https://doi.org/10.7554/eLife.37851.008
The following source data and figure supplements are available for figure 3:
Source data 1. Comparison of Bcl11b allelic expression between wildtype and mutant dual reporter mice in early thymic populations.
DOI: https://doi.org/10.7554/eLife.37851.016
Figure supplement 1. Levels of mono-allelic Bcl11b expression in thymus subsets: mono-allelic expression can persist throughout thymic development.
DOI: https://doi.org/10.7554/eLife.37851.009
Figure supplement 1—source data 1. Percentages of mono- and bi-allelic expressing cells in specific thymic populations analyzed for wildtype
(Bcl11bYFP/mCh(neo)) and mutant (Bcl11bYFPDEnh/mCh(neo)) dual reporter mice.
DOI: https://doi.org/10.7554/eLife.37851.010
Figure supplement 2. Mono-allelic Bcl11b expression persists in peripheral splenic T-cell subsets and is cell autonomous.
DOI: https://doi.org/10.7554/eLife.37851.011
Figure supplement 2—source data 1. Percentages of mono- and bi-allelic expressing cells in specific spleen populations analyzed for wildtype
(Bcl11bYFP/mCh(neo)) and mutant (Bcl11bYFPDEnh/mCh(neo)) dual reporter mice.
DOI: https://doi.org/10.7554/eLife.37851.012
Figure supplement 3. Cell autonomy of Bcl11b expression control in hematopoietic chimeric mice.
DOI: https://doi.org/10.7554/eLife.37851.013
Figure supplement 3—source data 1. Percentages of mono- and bi-allelic expressing cells in thymic and splenic populations analyzed for wildtype
(Bcl11bYFP/mCh(neo)) and mutant (Bcl11bYFPDEnh/mCh(neo)) chimeric mice.
DOI: https://doi.org/10.7554/eLife.37851.014
Figure supplement 4. Thymocytes from homozygous mutant enhancer Bcl11bYFPDEnh/YFPDEnh mice are able to generate T-cell subsets expressing
Bcl11b at normal levels relative to wild-type enhancer Bcl11b YFP/YFP mice.
DOI: https://doi.org/10.7554/eLife.37851.015
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A parallel trans-acting step enables expression from an activated
Bcl11b locus
The known transcriptional regulators of Bcl11b—TCF-1, Gata3, Notch1 and Runx1—are already
strongly expressed prior to entering the DN2 stage, suggesting they are not limiting for Bcl11b acti-
vation in DN2 cells. The data presented above show that cis-acting mechanisms can substantially
slow activation at individual alleles. However, additional trans-acting factors or post-translational
changes in these factors could still limit the kinetics of Bcl11b activation, working either upstream of
the cis-opening mechanism or as a separate, independent requirement. To gain insight into whether
such trans-acting inputs are necessary to explain the observed dynamics, and how they could act
together with the cis-acting step, we developed a set of minimal models requiring the cis-activating
step either alone or together with an additional trans-acting step (see Appendix for model details).
While the analysis is subject to technical limitations such as fluorescent protein sensitivity and time
delays in expression, and the actual biological behavior is undoubtedly more complex, these minimal
models, nevertheless, enable discrimination among broad classes of behavior.
To obtain unbiased estimates of the population fractions from imaging data (Figure 2), we fit
four two-dimensional Gaussians to single-cell Bcl11b-YFP and Bcl11b-mCherry data (see
Materials and methods for details). We note that estimated population fractions increased after a
delay (Figure 4B, gray-shaded area), due to a time lag in fluorescence accumulation and detection
after activation (Figure 4—figure supplement 1). We accounted for this lag by incorporating a fixed
time delay into all of our model fits (see Materials and methods).
In the simplest ‘cis only’ model, we assume that only the cis-activation step is required for Bcl11b
activation in DN2 stage, with all required trans-acting steps having occurred prior to the ETP-DN2
transition (Figure 4A, left). Because cis-activation is controlled at each allele by a single rate con-
stant, this model predicts a substantial lag between the appearance of mono-allelic cells, which
require one cis-activation event, and the appearance of bi-allelic cells, which require two indepen-
dent events (Appendix). By contrast, in experiments, bi-allelic cells accumulated immediately
(Figure 4B and Figure 4—figure supplement 1), without a substantial lag relative to mono-allelic
ones, resulting in a poor fit of the data to the cis-only model (Figure 4A). These results rule out the
simplest cis-only model, and suggest that additional trans events may still limit Bcl11b expression at
the DN2 stage.
We next considered two models in which trans-acting events affect Bcl11b activation. In the
‘sequential trans-cis’ model, a trans step must occur prior to the cis-activation step (Figure 4A). This
trans step could represent activation of a factor or epigenetic regulator that is necessary for cis-acti-
vation. In the ‘parallel trans-cis’ model, both cis and trans steps are similarly necessary, but can occur
in either order (Figure 4A). In this case, the trans step could represent activation of a factor that
drives Bcl11b transcription, but only from a cis-activated locus. While our models only consider the
DN2 stage, we note that they allow for some events to occur prior to the ETP-DN2a transition
(Figure 4A, gray dotted arrows). When the trans-acting step is rate limiting, both of these models
reduce bi-allelic lag by allowing the two alleles to turn on in relatively quick succession (in either
model) or simultaneously (in the parallel model). For this reason, both the sequential and parallel
trans-cis models reduced the lag prior to accumulation of bi-allelic cells, and hence fit the data signif-
icantly better than the ‘cis only’ model (Figure 4B, p<0.01 for both models).
While the sequential and parallel models show similar bulk behavior, they make divergent predic-
tions about the distributions of mono-allelic and bi-allelic expression states within clonal lineages.
For example, in the sequential model, silent progenitors are equally likely to activate one or the
other Bcl11b allele, and are thus more likely to show mono-allelic expression from both alleles in sin-
gle clones (Figure 4D, ‘mixed mono-allelic’). In contrast, in the parallel model, non-expressing pro-
genitors could have one cis-activated but unexpressed Bcl11b allele due to absence of the trans
step. Clonal descendants of such cells would be predisposed to show mono-allelic expression from
the same allele before activating the second (Figure 4D, ‘single mono-allelic’). Therefore, to discrim-
inate between sequential and parallel activation models, we used Monte-Carlo methods to simulate
the dynamics of Bcl11b activation in all descendants of a single starting cell over four generations
for each of the two models (Appendix), using the parameters that gave the best fits to the global
time course data in Figure 4B. Altogether, we generated and analyzed N = 30,000 clonal lineages
for each model.
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Figure 4. A trans-acting step, occurring in parallel with the cis-acting step, provides an additional input for Bcl11b activation. (A) Candidate models for
Bcl11b activation from the DN2 stage, involving a single cis-acting switch (top left), sequential trans-, then cis-acting switches (bottom left), and parallel,
independent trans- and cis- acting switches (right). (B) Plots show best fits of different models to the time evolution of Bcl11b allelic activation states,
observed by timelapse imaging (Figure 2). Gray-shaded area indicates time delay for detection of indicated allelic state as a result of the time required
for stable fluorescence protein accumulation. Best fit rate constants indicated in legend. (C) Bar charts show reduced chi-squared values for each model
fit, that is the normalized sum-squared fit errors over all time points and allelic states, divided by the degrees of freedom (d.f.) (see Materials and
methods). Both sequential and parallel trans-cis models fit the data significantly better than the cis-only model (F-test, F = 12.2, p=0.0052, sequential vs.
cis-only model; F = 8.13, p=0.021, parallel vs. cis-only model). (D) Three possible classes of Bcl11b activation states observable from clonal lineage data.
Lineage trees and transition diagrams show examples of simulated lineages that fall into the indicated classes. (E) Pie charts show expected distribution
of allelic activation states predicted for clonal lineages of non-expressing progenitors in either the sequential (left) or the parallel (right) trans-cis model,
obtained from N = 30,000 simulations, using parameters derived from bulk fitting (see Appendix). (F) Pie chart (left) shows observed distribution of
activation states observed across an entire imaging time course. Colored scatterplots (right) show Bcl11b-mCh versus Bcl11b-YFP levels of single-cell
lineages, falling into the indicated categories. Clones were scored according to observable fluorescence across an entire developmental trajectory,
from 0 hr (cyan) to 120 hr (purple). The observed frequency of clones with ‘single mono-allelic’ expression of Bcl11b (7/9 = 77%) is significantly different
than that predicted for the sequential trans-cis Model (20.1%, **- p<0.001, c2 = 14.9, d.f. = 1), but not significantly different from that predicted for the
parallel trans-cis Model (63.9%, c2 = 0.27, d..f = 1, n.s.). Results are representative of three independent experiments. See Figure 4—figure
supplement 2 for data for independent replicate experiments.
DOI: https://doi.org/10.7554/eLife.37851.017
The following source data and figure supplements are available for figure 4:
Source data 1. Quantitative analysis of timelapse imaging data used to test three minimal models.
DOI: https://doi.org/10.7554/eLife.37851.020
Figure 4 continued on next page
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As intuitively expected, the sequential trans-cis model predominantly generated ‘mixed mono-
allelic’ clones containing cells with mono-allelic expression of both alleles, with or without bi-alleli-
cally expressing cells (Figure 4D,E, ‘mixed mono-allelic’). These distributions reflect the most likely
event trajectory in the sequential model, in which independent, unsynchronized cis-activation events
occur at each Bcl11b locus in different cells from a single ancestor. Within a cohort of clonal
descendants competent to activate the cis-step, the first-activated allele choice occurs indepen-
dently in each cell, generating multiple paths towards bi-allelic Bcl11b activation within a single
clone. By contrast, the parallel model generated a much smaller fraction of such ‘mixed mono-allelic’
clones, and predominantly generated clones in which mono-allelic expression was restricted to the
same allele across most cells (Figure 4D,E, ‘single mono-allelic’). This intra-clonal bias arises when
the cis-acting step at one locus precedes the trans-step, forcing still-non-expressing DN2a precur-
sors to preferentially activate that locus once the trans-acting event occurs (Figure 4D). Because the
rate of cis-activation is low (tc ~ 4–6 days in this model), multiple individual cells can be generated
within a clone that have inherited the same activated allele of the locus, prior to full bi-allelic expres-
sion. Moreover, the parallel but not the sequential trans-cis model gave rise to a small fraction of
clones that showed only bi-allelic expression (Figure 4D,E, ‘bi-allelic only’), reflecting the activation
of the trans-limiting step in cells that had already undergone cis-activation of both Bcl11b copies.
To discriminate experimentally between these two models, we quantified the distribution of
Bcl11b allelic activation states generated in clonal lineages from progenitors starting with no Bcl11b
activation, observed by timelapse microscopy as described above (Figure 2). Within a clone, we
most frequently observed mono-allelic expression from only one specific allele, with or without bi-
allelically expressing cells (Figure 4F ‘single mono-allelic’, light green, 7/9 clones, Figure 4—figure
supplement 2; similar results observed over three independent experiments), but only rarely
observed mono-allelic expression from both loci within the same clone (Figure 4F, ‘mixed mono-
allelic’, gray, 1/9 clones). The observed percentage of ‘single mono-allelic’ expressing clones (7/
9 = 77%) was significantly greater than that expected from the sequential trans-cis model (20.4%,
p<0.005). Moreover, in one clone, we observed concurrent activation of both alleles (Figure 4F), a
behavior that would have been exceedingly rare in a sequential model (none observed in 30,000 sim-
ulations). Together, these results suggest that a trans-acting step, acting in parallel with the cis-act-
ing step, controls Bcl11b expression.
Notch signaling controls the parallel trans-acting step in Bcl11b
activation
Notch signaling drives T-cell fate commitment and provides an important input for Bcl11b expres-
sion. While not required to maintain Bcl11b expression in committed cells, it acts earlier to enhance
the probability of all-or-none Bcl11b expression at the DN2 stage and stabilize Bcl11b expression
shortly after activation, preventing the re-silencing that still can occur in a small fraction of newly
expressing cells (Kueh et al., 2016). The Notch intracellular domain is diffusible in the nucleus, but
could affect Bcl11b activation by modulating either the cis or trans step in the parallel model. For
example, Notch signaling could activate a trans factor that drives Bcl11b transcription from a cis-acti-
vated locus, and thereby alter the fraction of cells that express Bcl1b from a cis-activated locus.
Alternatively, Notch could affect the rate of the cis-activation process, for instance by enhancing the
activity of chromatin-remodeling enzymes on the Bcl11b promoter or enhancer, in which case it
might alter the ratio of mono-allelic to bi-allelic activation states. To distinguish between these cases,
we first experimentally analyzed the effects of removing Notch signaling on Bcl1b allelic expression
patterns, and then compared the results to predictions based on corresponding perturbations in the
parallel trans-cis model.
We sorted DN2 cells with no expression, mono-allelic expression or bi-allelic expression of Bcl11b
as initial populations, and then cultured them either on OP9-DL1 or OP9-Control feeders to maintain
Figure 4 continued
Figure supplement 1. Least-squares fitting of 2D histograms of Bcl11b expression levels.
DOI: https://doi.org/10.7554/eLife.37851.018
Figure supplement 2. Clones show mono-allelic expression from a single predominant allele during Bcl11b activation.
DOI: https://doi.org/10.7554/eLife.37851.019
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or remove Notch signaling, respectively. After 4 days, we analyzed the resulting Bcl11b allelic
expression states using flow cytometry (Figure 5A).
DL1 removal affected the distribution of Bcl11b allelic expression states differently depending on
the state of the starting cell population. For progenitors with no initial Bcl11b expression, DL1
removal decreased the total fraction of cells that subsequently expressed Bcl11b from either allele
from 0.9 to 0.5 (sum of mono-allelic and bi-allelic expressing cells, Figure 5A), as expected from the
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Figure 5. Notch signaling controls a parallel trans-acting step for Bcl11b activation. BM-derived DN2 progenitors with different Bcl11b allelic activation
states were sorted, cultured on either OP9-Control (-Notch) or OP9-DL1 (+Notch) monolayers for four days, and analyzed using flow cytometry. (A) Flow
cytometry plots show Bcl11b-mCherry versus Bcl11b-YFP expression levels in analyzed cells. Percentages of non-expressing, mono-allelic expressing
(both YFP and mCherry) and bi-allelic expressing cells were used to calculate the locations in the phase space. Note that when Notch signaling is
withdrawn from bi-allelically expressing cells, they downregulate both alleles coordinately (green-shaded arrow). (B) Phase space diagrams
experimentally obtained from analysis of flow cytometry data. Points in phase space represent the average of 2–4 replicate data points in a single
experiment (hollow circles). Inset shows final activation states of bi-allelic starting progenitors upon Notch withdrawal. Results shown are representative
of two independent experiments. (C–D) Predicted phase space diagrams for fraction of bi-allelic expressing cells (Fb) against the fraction of mono-allelic
expressing cells (Fm, YFP+ and mCh+ combined), for either the sequential trans-cis activation model (C), or the parallel trans-cis model (see Appendix
for details). Black (colored) dotted lines connect initial state to the normal (perturbed) final state. Note that actual developmental trajectories may be
curved (not shown). Arrows show predicted shifts in final state due to the indicated perturbations. Note that perturbations affect both the rates and
reversibility of the indicated reactions. See also Figure 5—figure supplement 1.
DOI: https://doi.org/10.7554/eLife.37851.021
The following source data and figure supplement are available for figure 5:
Source data 1. Flow Cytometry Analysis of BM-derived DN2 progenitors cultured in the presence or absence of Notch.
DOI: https://doi.org/10.7554/eLife.37851.023
Figure supplement 1. Notch controls a parallel trans-acting step for Bcl11b activation.
DOI: https://doi.org/10.7554/eLife.37851.022
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known positive effect of Notch on Bcl11b activation (Kueh et al., 2016). This reduction dispropor-
tionately affected mono-allelic expressing cells, such that the fraction of mono-allelic expressing cells
relative to bi-allelic expressing cells decreased (from ~0.8 to 0.4, Figure 5A). In progenitors starting
with mono-allelic Bcl11b expression, DL1 removal showed a large percentage reduction in the
mono-allelic population, with a smaller reduction in the bi-allelic population (~14% versus 20% reduc-
tion, from Figure 5A). Finally, in bi-allelic expressing Bcl11b progenitors, most cells maintained
expression despite Notch removal, as expected (Kueh et al., 2016), but a small fraction (~0.06) lost
expression of both Bcl11b alleles entirely, reverting directly from the bi-allelic to a non-expressing
state (Figure 5A, green arrows). To visually summarize these effects of Notch withdrawal, we repre-
sented the distribution of non-expressing, mono-allelic, and bi-allelic expressing cell states in the
population in each condition from each starting population as points within a triangular region of
allowed states in a single diagram (Figure 5B).
To interpret these experimental results, we compared the observed effects with predicted effects
of a step-like perturbation in either the cis- or the trans-acting steps of the model (see Appendix). In
order to account for reversibility in Bcl11b activation observed upon DL1 removal (Figure 5A), per-
turbation of the cis or trans step was implemented by both decreasing its forward rate and increas-
ing its backwards rate. Additionally, all perturbations were assumed to have a weaker effect on
transitions to or from the Bcl11b bi-allelic expressing state compared to transitions to or from the
mono-allelic state. This assumption was designed to reflect the reduced impact of Notch signal with-
drawal on cells starting with bi-allelic Bcl11b expression (Bcl11b inactivation was observed in ~6% of
bi-allelic expressing progenitors versus ~15–18% of mono-allelic expressing progenitors, Figure 5A).
We simulated the model with different strengths of cis or trans perturbations, and generated distri-
butions of Bcl11b allelic activation states from non-expressing, mono-allelic, and bi-allelic starting
populations.
Perturbation of the cis-acting step decreased the total fraction of cells expressing Bcl11b from all
initial cell populations, as expected (Figure 5C). However, in contrast to experimental observations,
this simulated perturbation increased, rather than decreased, the ratio of mono-allelic expressing
cells to bi-allelic expressing cells (Figure 5C). It also caused bi-allelic expressing cells to sequentially
turn off Bcl11b one allele at a time, rather than simultaneously as observed experimentally. Simu-
lated perturbation of the cis-acting step thus did not match the observed effects of Notch with-
drawal (Figure 5B,C).
By contrast, perturbation of the trans-acting step in the model produced effects resembling
Notch withdrawal. First, it led to direct reversion of bi-allelic expressing progenitors to a non-
expressing state, without passing through mono-allelic intermediates (Figure 5D, green arrows).
Simultaneous inactivation of both alleles is difficult to reconcile with Notch affecting independent
(cis) effects at each allele but is expected in response to removal of a trans-acting factor required for
maintaining expression (Figure 5B). Second, unlike the cis perturbation, the trans perturbation did
not increase the mono-allelic to bi-allelic ratio. In the simplest case, where all trans steps are uni-
formly affected by Notch, the trans perturbation is independent of the distribution of cis states (Fig-
ure 5—figure supplement 1), and therefore the mono- to bi-allelic ratio remains constant. When
the trans perturbation more strongly affects mono-allelic cells, as we assume here, the mono- to bi-
allelic ratio decreases, opposite to observed effects of the cis perturbation but consistent with
experimental results.
Additionally, we also considered a third possibility in which Notch controls a necessary trans-act-
ing step occurring strictly prior to cis-activation, as postulated by the sequential trans-cis model (Fig-
ure 5—figure supplement 1). In this case, progenitors that express one or both Bcl11b alleles
would no longer be affected by Notch withdrawal, inconsistent with the experimental observations
(Figure 5B). Taken together, these results strongly suggest that a separate Notch-dependent trans-
acting event, occurring in parallel with Bcl11b locus activation, is necessary for Bcl11b activation and
T-cell lineage commitment.
Bcl11b activation can only occur over a limited developmental window
Given the finite rate of cis- and trans-activation steps, all cells would be expected to eventually acti-
vate both Bcl11b copies. However, a small fraction of cells were consistently found to express
Bcl11b mono-allelically in thymic and peripheral T cell subsets (Figures 1 and 3B,C and Figure 3—
figure supplements 1,2). This result suggested that activation might be possible only for a limited
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time and that cells might lose competence to activate any still-silent Bcl11b locus as they develop.
To test this hypothesis, we sorted mono-allelically expressing cells from different developmental
stages, cultured them in vitro on OP9-DL1 monolayers for 4 days, and analyzed expression of both
Bcl11b alleles (Figure 6A). The already-active copy retained active expression throughout the assay,
as expected. However, the frequency of activation of the initial silent Bcl11b allele varied strongly
with developmental stage. Activation occurred efficiently at the DN2 stage (DN2A and DN2B com-
bined) but dropped sharply as cells progressed to DN3 (~80% versus~15% activated after 4 days,
Figure 6A), and dropped even further at the double positive (DP) and CD4 single positive stages
(~1.5% and 2.4%, respectively, Figure 6A). Equivalent results were obtained regardless of whether
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Figure 6. Probabilistic Bcl11b activation occurs within a limited developmental time window. Cells expressing only one Bcl11b allele at the indicated
stages were sorted from thymocytes, cultured for 4d on OP9-DL1 monolayers, and analyzed for activation of the initially inactive Bcl11b allele using flow
cytometry. (A) Flow plots (left) show Bcl11b-mCh versus Bcl11b-YFP expression levels for descendants of cells that had mono-allelic expression at the
indicated stages of development; bar charts (right) show the fraction of progenitors from different stages that activate the silent Bcl11b allele upon
culture. Data represent mean and standard deviation of 4–5 replicates, derived from two independent experiments. The competence to activate the
silent Bcl11b allele decreases upon progression to the DN3 stage and beyond. (B) Flow plots (left) show Bcl11b-mCh versus Bcl11b-YFP expression
levels for DN2 or DN3 progenitors with either an intact YFP allele enhancer (top) or a disrupted YFP allele enhancer (bottom). Bar chart (right) shows the
fraction of cells activating the silent Bcl11b allele upon re-culture. Data show that enhancer disruption reduces the Bcl11b activation advantage in DN2
cells as compared to DN3 cells. Data represent mean and standard deviation of three replicates from two independent experiments.
DOI: https://doi.org/10.7554/eLife.37851.024
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the experiment started with active wildtype YFP and mCherry alleles (Figure 6A). These results indi-
cate that cis-activation of Bcl11b predominantly occurs during DN2 and DN3 stages.
This DN2-stage preference for Bcl11b activation competence could arise from stage-specific
activity of the identified distal enhancer. To test this hypothesis, we compared the activation kinetics
of intact and enhancer-disrupted YFP alleles in sorted progenitors expressing only the Bcl11b
mCherry allele. When the input cells were DN2 cells, the enhancer-disrupted YFP allele showed
markedly less activation over the next four days than the intact YFP allele (70% versus 32%,
Figure 6B). However, using input cells sorted at the DN3 stage, no differences in activation propen-
sity were observed, with both wildtype and disrupted enhancer alleles showing the same attenuated
degree of activation (~17%). These results suggest that the Bcl11b enhancer works specifically to
enhance cis-activation of Bcl11b at the DN2 stage.
Discussion
Stochastic epigenetic control switches have been described in yeasts, plants, and, more recently,
constructed in synthetic systems (Berry et al., 2017; Bintu et al., 2016; Hathaway et al., 2012;
Keung et al., 2014; Xu et al., 2006), yet their roles in controlling fate decisions in vertebrate devel-
opmental systems are not well understood. Specifically, it is not clear when epigenetic states simply
respond passively to ‘upstream’ developmental changes in transcription factor activity, and when
they actively impose distinct temporal constraints on transcription factor effects. By separately fol-
lowing the two chromosomal copies of Bcl11b in single cells, we found that the decision to turn on
Bcl11b, and the ensuing transition to T-cell fate, involves a stochastic, irreversible rate-limiting cis-
activation step that occurs on each chromosomal allele of the Bcl11b gene itself. The cis-acting step
occurs at a low enough rate (kC ¼ 4:2 3:3ð Þ  10
 3/hr, Figure 4A) to generate numerous mono-
allelically expressing cells as intermediates, and is stable enough to propagate the same mono-allelic
activation state through multiple rounds of cell division in individual clones. In particular, by generat-
ing delays of multiple days and cell generations prior to differentiation, the cis-acting switch also
indirectly controls the overall degree of proliferation of the progenitor pool. These results thus dem-
onstrate that stochastic, epigenetic events on individual gene loci can fundamentally limit the timing
and outcome of mammalian cell fate decisions, as well as the population structure of the resulting
differentiated population.
Slow, stochastic Bcl11b activation is controlled in part by an enhancer far downstream from the
Bcl11b promoter, on the opposite end of the same topologically associated domain. Multiple known
epigenetic changes that occur on the Bcl11b locus could participate in the processes whose dynam-
ics we have measured here. The distal enhancer could recruit chromatin regulators that clear repres-
sive chromatin modifications from the Bcl11b locus. In its silent state, the Bcl11b promoter and gene
body are covered by DNA methylation and histone H3K27me3 modifications (Hu et al., 2018;
Ji et al., 2010; Zhang et al., 2012). Chromatin regulators recruited by the enhancer could disrupt
repressive modifications in their vicinity, catalyzing a phase transition that results in cooperative, all-
or-none removal of repressive marks on the entire gene locus (Larson et al., 2017; Strom et al.,
2017). As another possibility, the distal enhancer could recruit trans- factors that facilitate its T-line-
age-specific looping with the Bcl11b promoter and its subsequent activation (Li et al., 2013). In early
T-cell progenitors, the Bcl11b promoter establishes new contacts with its distal enhancer, resulting
in de novo formation of an altered topological associated domain, with boundaries defined by these
two elements (Hu et al., 2018; Isoda et al., 2017). Trans- regulators of DNA loop extrusion that
associate with the distal enhancer, whose binding may be facilitated by non long-coding RNA tran-
scription (Isoda et al., 2017), may stabilize these looping interactions (Fudenberg et al., 2016; Nas-
myth, 2001; Riggs, 1990; Sanborn et al., 2015), which may release Bcl11b from the repressive
environment of the nuclear periphery and permit its activation (Isoda et al., 2017). The evidence for
such epigenetic differences associated with the Bcl11b locus in T and non-T cells have been known
for some time, but the functional impacts of cis-acting mechanisms on locus activation dynamics has
been unknown until now. Ultimately, any of these mechanisms that are rate-limiting will have to
account for the stochastic nature of Bcl11b locus activation, its exceptionally long activation time
constant, and its all-or-none, irreversible nature, demonstrated here. Dissecting the molecular and
biophysical basis of these striking emergent properties will be the subject of future investigation.
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Mathematical modeling, together with perturbation analysis, are consistent with Bcl11b expres-
sion requiring a separate Notch signal-dependent trans- event that is needed in parallel with Bcl11b
cis-activation (Figure 7). The comparable slow rate constants for parallel cis and trans steps imply
that a substantial fraction of cells can undergo the cis-acting step prior to trans-activation and
observable Bcl11b expression. Furthermore, although the experiments here all start with DN2A pro-
genitors, relevant dynamics may extend to earlier stages. In fact, the cis-acting step could potentially
occur within the preceding ETP stage or during the ETP-DN2a transition (Kueh et al., 2016). Consis-
tent with this hypothesis, changes in Bcl11b chromatin state associated with gene activation can
already be observed at the ETP stage (Isoda et al., 2017; Zhang et al., 2012). Furthermore, previ-
ous work showed that knockdown of Gata3 and TCF-1, which first turn on at the ETP stage and are
required for Bcl11b activation but not for subsequent events, impact Bcl11b activation more strongly
in ETP cells than in DN2A cells that have not yet activated Bcl11b, suggesting that many cells may
enter DN2A after cis-activation has already occurred. Looking ahead, a more complete model will
therefore have to span multiple stages of T cell development.
How widespread are stochastic epigenetic switches of the type analyzed here? The only other
regulatory switch whose individual allele dynamics been similarly characterized, to our knowledge,
occurs in the plant vernalization system, which controls flowering in response to periods of cold tem-
perature. Specifically, exposure to cold causes silencing of FLC, a master repressor of flowering. An
obvious regulatory difference between the two systems is in the direction of regulation, with FLC
undergoing silencing and Bcl11b undergoing activation. Nevertheless, the two systems share com-
mon dynamic features. Like Bcl11b, FLC silencing involves an all-or-none switch that occurs stochasti-
cally, independently at distinct gene copies in the same cell, and is stably inherited during
cell division (Angel et al., 2011; Berry et al., 2015; Yang et al., 2017). Also like Bcl11b, silencing of
the FLC locus occurs at rates lower than that of cell division, giving rise to distinct mono- and bi-alle-
lic expressing states that persist over multiple cell generations. In the vernalization system, FLC
silencing was shown to occur in two steps: First, repressive H3K27me3 modifications nucleate near
the promoter, producing a metastable (reversible) silent state. Second, these marks spread across
the locus, locking the locus into a more stable silent state (Yang et al., 2017). With Bcl11b, we do
OFF ON
Notch
Bcl11b
(early)
TCF-1
GATA3
rate limiting
trans step
rate limiting
cis step
Figure 7. Model of Bcl11b regulation by parallel cis and trans-limiting steps. Bcl11b activation requires two rate-
limiting steps: a switch of the Bcl11b locus from an inactive to active epigenetic state, and the activation of a trans
factor is necessary for transcription of Bcl11b from an activated locus. Notch signaling activates TCF-1 and GATA3
in early thymic progenitors (Garcı´a-Ojeda et al., 2013; Scripture-Adams et al., 2014; Weber et al., 2011), and
these two factors may act on the identified distal enhancer to control the rate-limiting cis step on the Bcl11b locus
(green). In parallel, Notch promotes the activation of a trans factor (red) that is necessary for transcription from a
cis-activated Bcl11b locus. The cis and trans-limiting steps together control the dynamics of Bcl11b expression and
T-cell lineage commitment.
DOI: https://doi.org/10.7554/eLife.37851.026
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not yet know whether chromatin modifications are causally responsible for activation, nor do we
know whether the gene passes through a metastable intermediate as FLC does. In both systems,
upstream trans-acting factors – Vin3 for FLC and Gata-3 and TCF-1 for Bcl11b – control the stochas-
tic rate of silencing or activation, respectively, but do not deterministically specify the transcription
rates of the individual gene. For FLC, it is not yet known whether additional parallel trans-acting
steps are also required, as is the case with Bcl11b. Analyzing the dynamics of allelic silencing using
the framework described above could provide insight into this question. While the schemes likely
differ between the two systems, the many similarities in the dynamics of regulation between these
two very different contexts suggest that stochastic epigenetic switches are likely to be prevalent.
Slow, stochastic epigenetic switches, similar to the one we describe here, may allow cells to tune
the size and composition of differentiated tissues. By using trans-acting inputs that modulate activa-
tion probabilities, such epigenetic switches could translate differences in input duration to changes
in the fraction of output cells activated (Bintu et al., 2016), a strategy that could enable tunable con-
trol of cellular proportions in a developing tissue or organ. Moreover, a striking aspect of this mech-
anism is its ability to generate populations of mature T cells that are mosaic in the status of their
activation of the two Bcl11b alleles. Indeed, the differential distribution of mono-allelically express-
ing cells that we see among distinct functional T-cell subsets suggests the potential of non-uniform
allelic activity to alter function or selective fitness. The increased fraction of mono-allelically express-
ing cells that appear when an enhancer complex is weakened is a strong phenotype at the single cell
level that could be relevant to enhancer polymorphisms in natural populations, although its impact
could easily be underestimated by more conventional gene expression analyses.
Here, we have illustrated a general approach that can reveal the dynamics of epigenetic control
mechanisms, determine their prevalence in the genome, and elucidate their functional roles in multi-
cellular organism development and function. Stochastic epigenetic switches, similar to the one
uncovered here, may constitute fundamental building blocks of cell fate control circuits in mamma-
lian cells. As cells transition from one developmental state to another, they undergo concerted trans-
formations in the chemical modification states or physical conformations of many regulated genes.
These changes could reflect more widespread roles for epigenetic mechanisms in controlling cell
state transition timing.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation Source or reference Identifiers Additional information
Recombinant
DNA reagent
pTarget Bcl11b
IRES-H2Bm
Cherry-neo/3pUTR
This paper N/A Gene targeting vector
with IRES-H2B-mCherry-
loxP-neo-loxP cassette
knocked into 3’
UTR of Bcl11b
Recombinant
DNA reagent
pTarget Bcl11b
dEnh-hygro
This paper N/A Gene targeting vector with
Enhancer replaced by
hygromycin cassette
Recombinant
DNA reagent
FRT-PGK-gb2-
hygromycin-FRT
cassette
Genebridges Cat# A010
Recombinant
DNA reagent
MSCV IRES
H2B-mCerulean
Kueh et al., 2013 N/A
Recombinant
DNA reagent
pCL-Eco Imgenex Cat# NBP2-29540
Continued on next page
Ng et al. eLife 2018;7:e37851. DOI: https://doi.org/10.7554/eLife.37851 17 of 38
Research article Computational and Systems Biology Developmental Biology
Continued
Reagent type
(species) or
resource Designation Source or reference Identifiers Additional information
Strain, strain
background (mouse)
Bcl11bYFP(neo)/mCh(neo) This paper N/A Two color reporter mice
generated from breeding
animals homozygous for
either Bcl11b YFP(neo)
or Bcl11b mCh(neo). See
Materials and methods
for details.
Strain, strain
background (mouse)
Bcl11bmCh(neo)/mCh(neo) This paper N/A Homozygous
Bcl11b mCh(neo)
reporter mice used to
generate two color reporter
mice. Derived from Bcl11b
YFP/mCh(neo) F0 chimeric
mice. See Materials and
methods for details.
Strain, strain
background (mouse)
Bcl11bYFP/mCh(neo) This paper N/A Control mice for comparing
the effects of the enhancer
on Bcl11b expression.
Generated by targeting
Bcl11b mCherry gene
targeting vector to V6.5
mouse embryonic stem
(ES) cells with single modified
Bcl11b mCitrine dneo allele.
See Materials and methods
for details.
Strain, strain
background (mouse)
Bcl11bYFPdEnh/mCh(neo) This paper N/A Two color reporter mouse
with Bcl11b enhancer deleted.
Generated by targeting dEnh
gene target vector to V6.5
mouse ES cells with genotype
Bcl11b YFP/mCh(neo). See
Materials and methods
for details.
Strain, strain
background (mouse)
Bcl11bYFPdEnh/dEnh This paper N/A Homozygous deleted
enhancer mice generated
from Bcl11b YFP
dEnh/mCh(neo) mice.
See Materials and methods
for details.
Strain, strain
background (mouse)
CD45.1 C57BL/6:
B6.SJL-Ptprca
Pepcb/BoyJ
Jackson Laboratory Stock No# 002014
Cell line (mouse) OP9-DL1-GFP Schmitt and Zu´n˜iga-Pflu¨cker, 2002 N/A
Cell line (mouse) OP9-Mig Schmitt and Zu´n˜iga-Pflu¨cker, 2002 N/A
Cell line (mouse) OP9-DL1-hCD8 Kueh et al., 2016 N/A
Cell line (human) Human Phoenix-ECO ATCC Cat# CRL-3214
Antibody Anti-mouse CD8a
Biotin (clone 53–6.7)
eBioscience Cat# 13-0081-86;
RRID:AB_466348
(1:100)
Antibody Anti-mouse TCRb
Biotin (clone H57-597)
eBioscience Cat# 13-5961-85;
RRID:AB_466820
(1:100)
Antibody Anti-mouse TCRgd
Biotin (clone GL3)
eBioscience Cat# 13-5711-85;
RRID:AB_466669
(1:100)
Antibody Anti-mouse Ter119
Biotin (clone TER-119)
eBioscience Cat# 13-5921-85;
RRID:AB_466798
(1:100)
Antibody Anti-mouse NK1.1
Biotin (clone PK136)
eBioscience Cat# 13-5941-85;
RRID:AB_466805
(1:100)
Continued on next page
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Reagent type
(species) or
resource Designation Source or reference Identifiers Additional information
Antibody Anti-mouse Gr-1
Biotin (clone RB6-8C5)
eBioscience Cat# 13-5931-86;
RRID:AB_466802
(1:100)
Antibody Anti-mouse CD11c
Biotin (clone N418)
eBioscience Cat# 13-0114-85;
RRID:AB_466364
(1:100)
Antibody Anti-mouse CD11b
Biotin (clone M1/70)
eBioscience Cat# 13-0112-86;
RRID:AB_466361
(1:100)
Antibody Anti-mouse CD19
Biotin (clone 1D3/6D5)
eBioscience Cat# 13-0193-85;
RRID:AB_657658
(1:100)
Antibody Anti-mouse CD3e
Biotin (clone
145–2 C11)
eBioscience Cat# 13-0031-85;
RRID:AB_466320
(1:100)
Antibody Anti-human/mouse
B220 Biotin
(clone RA3-6B2)
eBioscience Cat# 13-0452-85;
RRID:AB_466450
(1:100)
Antibody Anti-mouse F4/80
Biotin (clone BM8)
eBioscience Cat# 13-4801-85;
RRID:AB_466658
(1:100)
Antibody Anti-mouse CD4
Biotin (clone GK1.5)
eBioscience Cat# 13-0041-85;
RRID:AB_466326
(1:100)
Antibody Anti-human/mouse
CD44 eFluor 450
(clone IM7)
eBioscience Cat# 48-0441-82;
RRID:AB_1272246
(1:300)
Antibody Anti-mouse CD25
Brilliant Violet 510
(clone PC61)
Biolegend Cat# 102041;
RRID:AB_2562269
(1:300)
Antibody Anti-mouse CD117
(cKit) APC-eFluor
780 (clone 2B8)
eBioscience Cat# 47-1171-82;
RRID:AB_1272177
(1:300)
Antibody Anti-mouse HSA
eFluor 450
(clone M1/69)
eBioscience Cat# 48-0242-82;
RRID:AB_1311169
(1:300)
Antibody Anti-mouse CD4
Brilliant Violet 510
(clone GK1.5)
Biolegend Cat# 100449;
RRID:AB_2564587
(1:300)
Antibody Anti-mouse CD8a
APC (clone 53–6.7)
eBioscience Cat# 17-0081-82;
RRID:AB_469335
(1:300)
Antibody Anti-mouse TCRb
APC-eFluor 780
(clone H57-597)
eBioscience Cat# 47-5961-82;
RRID:AB_1272173
(1:300)
Antibody Anti-mouse CD25
APC-eFluor 780
(clone PC61.5)
eBioscience Cat# 47-0251-82;
RRID:AB_1272179
(1:300)
Antibody Anti-mouse CD19
eFluor 450
(clone 1D3/6D5)
eBioscience Cat# 48-0193-82;
RRID:AB_2734905
(1:300)
Antibody Anti-mouse CD117
(cKit) APC (clone 2B8)
eBioscience Cat# 17-1171-82;
RRID:AB_469430
(1:300)
Antibody Anti-mouse CD45
APC-eFluor 780
(clone 30-F11)
eBioscience Cat# 47-0451-82;
RRID:AB_1548781
(1:300)
Antibody Anti-mouse CD25
APC (clone PC61.5)
eBioscience Cat# 17-0251-82;
RRID:AB_469366
(1:300)
Antibody Anti-mouse CD4
APC-eFluor 780
(clone GK1.5)
eBioscience Cat# 47-0041-82;
RRID:AB_11218896
(1:300)
Continued on next page
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Continued
Reagent type
(species) or
resource Designation Source or reference Identifiers Additional information
Antibody Anti-mouse CD8a
APC-eFluor 780
(clone 53–6.7)
eBioscience Cat# 47-0081-82;
RRID:AB_1272185
(1:300)
Antibody Anti-mouse CD45
APC (clone 30-F11)
eBioscience Cat# 17-0451-82;
RRID:AB_469392
(1:300)
Antibody Anti-mouse CD5
eFluor 450
(clone 53–7.3)
eBioscience Cat# 48-0051-82;
RRID:AB_1603250
(1:300)
Antibody Anti-mouse TCRgd
APC (clone GL3)
eBioscience Cat# 17-5711-82;
RRID:AB_842756
(1:300)
Antibody Anti-mouse CD49b
eFluor 450
(clone DX5)
eBioscience Cat# 48-5971-82;
RRID:AB_10671541
(1:300)
Antibody Anti-mouse NK1.1
APC (clone PK136)
eBioscience Cat# 17-5941-82;
RRID:AB_469479
(1:300)
Antibody Anti-mouse CD3e
APC-eFluor 780
(clone 145–2 C11)
eBioscience Cat# 47-0031-82;
RRID:AB_11149861
(1:300)
Antibody Anti-mouse TCRb
eFluor 450
(clone H57-597)
eBioscience Cat# 48-5961-82;
RRID:AB_11039532
(1:300)
Antibody Anti-mouse CD49b
Biotin (clone DX5)
eBioscience Cat# 13-5971-82;
RRID:AB_466825
(1:300)
Antibody Anti-mouse CD62L
APC (clone MEL-14)
eBioscience Cat# 17-0621-82;
RRID:AB_469410
(1:300)
Antibody Anti-mouse CD45.2
Brilliant Violet 510
(clone 104)
Biolegend Cat# 109837;
RRID:AB_2561393
(1:300)
Antibody Anti-mouse CD4
eFluor 450
(clone GK1.5)
eBioscience Cat# 48-0041-82;
RRID:AB_10718983
(1:300)
Antibody Anti-mouse CD45
eFluor 450
(clone 30-F11)
eBioscience Cat# 48-0451-82;
RRID:AB_1518806
(1:300)
Antibody Streptavidin
PerCP-Cyanine5.5
Biolegend Cat# 405214;
RRID:AB_2716577
(1:300)
Antibody Streptavidin Brilliant
Violet 510
Biolegend Cat# 405234 (1:300)
Peptide,
recombinant protein
Recombinant Human
Flt3-Ligand
PeproTech Cat# 300–19
Peptide,
recombinant protein
Recombinant Human IL-7 PeproTech Cat# 200–07
Peptide,
recombinant protein
Recombinant Human
Stem Cell Factor (SCF)
PeproTech Cat# 300–07
Peptide,
recombinant protein
Recombinant Mouse IL-6 eBioscience Cat# 14-8061-62
Peptide,
recombinant protein
Recombinant Mouse
Stem Cell Factor (SCF)
eBioscience Cat# 34-8341-82
Peptide,
recombinant protein
Recombinant Mouse IL-3 eBioscience Cat# 14-8031-62
Peptide,
recombinant protein
Retronectin Takara Cat# T100B
Peptide,
recombinant protein
DL1-extIgG Protein Varnum-Finney et al., 2000 N/A
Continued on next page
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Continued
Reagent type
(species) or
resource Designation Source or reference Identifiers Additional information
Software,
algorithm
FlowJo (v10.0.8) Tree Star N/A
Software,
algorithm
MATLAB (R2016a) MathWorks N/A
Other FuGENE 6
Transfection
Reagent
Promega Cat# E2691
Other MACS Streptavidin
Microbeads
Miltenyi Biotec Cat# 130-048-101
Other LS Columns Miltenyi Biotec Cat# 130-042-401
Other 250mm-diameter
PDMS circular
micromesh arrays
Microsurfaces Pty Ltd Cat# MMA-0250-100-08-01
Experimental model and subject details
Animals
Fo chimeric mice from Bcl11b
YFP/mCh(neo) and Bcl11bYFPDEnh/mCh(neo) ES-cell blastocyst injections were
all made in our lab (described in Materials and method Details). Founder animals were brought to
term and crossed in house to generate Bcl11bYFP(neo)/mCh(neo), Bcl11bYFP/mCh(neo), Bcl11bYFPDEnh/mCh
(neo), and Bcl11bYFPDEnh/mCh(neo) mice. CD45.1 C57BL/6 mice were purchased from Jackson Labora-
tory. All adult animals were used between 5 and 12 weeks of age. Both male and female mice were
used similarly in all studies. Animals used for these experiments were bred and maintained at the
Animal Facilities at both the California Institute of Technology and the University of Washington, and
animal protocols were reviewed and approved by the Institute Animal Care and Use Committees of
both institutions (Protocols #1445 and #1409, California Institute of Technology; Protocol #4397–01,
University of Washington).
Cells
Primary cells isolated from thymus, spleen, bone marrow, and fetal livers were cultured on a OP9-
DL1 or OP9-control stromal monolayer system (Schmitt and Zu´n˜iga-Pflu¨cker, 2002) at 37˚C in 5%
CO2 conditions with standard culture medium [80% aMEM (Gibco), 20% Fetal Bovine Serum (Sigma-
Aldrich), Pen-Strep-Glutamine (Gibco), 50 mM b-mercaptoethanol (Sigma)] supplemented with
appropriate cytokines (described in Materials and method Details). Both OP9-DL1 and OP9-control
cell lines were tested and found to be negative for mycoplasma contamination.
Method details
Construct designs
Gene targeting vectors for generating dual allelic Bcl11b fluorescent reporter and subsequent
enhancer knockout were constructed using a two-step bacterial artificial chromosome (BAC) recom-
bineering method. First, Bcl11b-BACs were modified to either insert a fluorescent reporter or dis-
rupt the enhancer sequence with a drug selection marker. An internal ribosome entry site (IRES)-
histone 2B-mCherry red fluorescent protein (mCh)-loxP-neomycin (neo)-loxP cassette with homology
arms targeting the 3’-untranslated region (UTR) of Bcl11b was derived from a similar histone 2B-mCi-
trine yellow fluorescent protein (YFP) gene targeting vector version published previously
(Kueh et al., 2016) and an IRES-H2B-mCherry-loxP-neomycin (neo)-loxP cassette. These two starting
plasmids were digested with restriction enzymes NheI and HindIII (New England Biolabs) to
exchange the fluorescent protein sequences. Homology arms flanking the 5’ and 3’ ends of the 1.9
kb enhancer (Enh) sequence to be replaced (chr12: 108,396,825–108,398,612, mm9 assembly;
chr12:107,158,615–107,160,462, in mm10) were attached to a FRT-PGK-gb2-hygromycin (hygro)-
FRT drug selection cassette through fusion PCR, and inserted into a cloning vector (pGEM-T-Easy,
Promega). Next, restriction enzymes were used to release the homology-flanked fluorescent or drug
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reporter cassettes, and the resultant linear fragments were introduced into recombineering E. Coli
strain SW102 containing appropriate BACs for specific targeting. The IRES-mCh-neo fragment was
linearized with AatII, SalI-HF, ScaI-HF and knocked into a BAC containing the entire Bcl11b gene
locus (RP24-282D6, from http://bacpac.chori.org). Restriction enyzmes XmnI, PspOMi, and SbfI
released the FRT-hygro-FRT cassette used to replace the enhancer sequence in a BAC containing
genomic regions downstream of the Bcl11b locus (RP23-445J15, from http://bacpac.chori.org). Cor-
rectly modified BACs were then selected using kanamycin or hygromycin in combination with chlor-
amphenicol, and verified by PCR and pulse-field gel electrophoresis analysis using the restriction
enzyme NotI (New England Biolabs).
A second recombineering reaction retrieved the targeting sequences from reporter modified
Bcl11b-BACs. The retrieval vector used to fetch the targeting sequence from the modified Bcl11b-
mCherry-neo BAC was made in a previous study (Kueh et al., 2016). For retrieval of the enhancer-
disrupted sequence, homology arms for retrieval were first generated using fusion PCR, then cloned
into a vector containing a Herpes Simplex Virus-Thymidine Kinase (HSV-TK) cassette using restriction
enzymes NotI and SpeI (New England Biolabs). Both retrieval vectors were linearized with PacI and
AscI (New England Biolabs), introduced into SW102 containing respective modified Bcl11b-BACs,
and retrieved targeting sequences between the homologous ends to generate the desired gene tar-
geting vectors. Clones that underwent correct retrieval reactions were selected using kanamycin or
hygromycin in combination with ampicillin, and verified with restriction enzyme digests and
sequencing.
The retroviral construct expressing IRES-H2B-mCerulean cyan fluorescent protein (CFP) used for
timelapse imaging experiments was generated in a previous study (Kueh et al., 2013). A complete
list of vectors used is provided in Key Resources Table.
Mouse generation
A series of genetic modifications were performed to generate different Bcl11b reporter mouse
strains used for this study (Figure 1—figure supplement 1). V6.5 mouse embryonic stem (ES) cells
with a single modified Bcl11b allele expressing the IRES-H2B-mCitrine-loxp-neo-loxp fluorescent
reporter were first transfected with Cre recombinase to excise the neomycin cassette. Subclones of
this line with a correct deletion of the neomycin cassette were then targeted with the IRES-mCherry-
neo gene targeting vector to generate dual allelic Bcl11b fluorescent reporter cells, and targeted
again with the DEnh-hygro cassette to delete the enhancer in one allele. After each targeting event,
recombinant ES cells grown on feeders were positively selected with antibiotics according to the cas-
sette inserted, and negatively selected with G418. Resistant clones were passaged onto feeder-free
conditions and screened using PCR and qPCR for correct targeting. Clones with the desired geno-
type were karyotyped for normal chromosome numbers before being injected into C57BL/6 blasto-
cyst embryos or subjected to subsequent gene targeting.
F0 chimeric mice from Bcl11b
YFP/mCh(neo) and Bcl11bYFPDEnh/mCh(neo) ES-cell blastocyst injections
were generated, and either analyzed at embryonic day 14.5 (E14.5) or brought to term for breeding.
Bcl11bYFP/mCh(neo) F0 chimeric mice were crossed to C57BL/6 mice, and the offspring containing
Bcl11b-IRES-mCherry-neo allele were then bred to homozygosity for this allele. Dual allelic
Bcl11bYFP(neo)/mCh(neo) mice with identical Bcl11b alleles except for fluorescent protein reporters
were generated from breeding Bcl11bmCh(neo)/mCh(neo) mice to previously produced Bcl11bYFP(neo)/YFP
(neo) mice (Kueh et al., 2016), and were used for in vitro assay studies of bone marrow derived
T-cells. Bcl11bYFPDEnh/mCh(neo) mice were generated in a similar manner by first breeding to C57BL/6
mice to generate enhancer deleted heterozygotes, then crossing mice to Bcl11bmCh(neo)/mCh(neo).
Bcl11bYFPDEnh/YFPDEnh mice were generated in parallel by crossing enhancer deleted heterozygotes
together. For experiments comparing the effects of the enhancer on Bcl11b expression, direct con-
trol Bcl11bYFP/mCh(neo) mice were generated from breeding Bcl11bYFP/YFP and Bcl11bmCh(neo)/mCh(neo)
animals. However, we have previously reported that the presence or absence of neo cassette does
not affect the Bcl11b reporter locus (Kueh et al., 2016), and do not observe any differences in
expression pattern in this study as well (see Figures 1 and 3).
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Cell purification
Thymocytes and splenocytes were purified from lymphoid organs removed from 4- to 6-week-old
normal and enhancer-deleted two-color Bcl11b reporter strains, and 2-month post-fetal liver precur-
sor transplantation CD45.1 chimeras prior to flow cytometry analysis or fluorescent activated cell
sorting (FACS). Harvested lymphoid organs were mechanically dissociated to make single cell sus-
pensions that were re-suspended in Fc blocking solution with 2.4G2 hybridoma supernatant (pre-
pared in the Rothenberg lab). Early stage thymocyte precursors to be analyzed (ETP, DN2A, DN2B,
DN3: Figures 1C and 3B, and Figure 3—figure supplement 1) or sorted (DN2, DN3: Figures 3D
and 6A), were first depleted of mature cell lineages using a biotin-streptavidin-magnetic bead
removal method. Thymocyte suspensions were labeled with biotinylated lineage marker antibodies
(CD8a, TCRb, TCRgd, Ter119, Gr-1, CD11c, CD11b, NK1.1), incubated with MACS Streptavidin
Microbeads (Miltenyi, Biotec) in HBH buffer (HBSS (Gibco), 0.5% BSA (Sigma-Aldrich), 10 mM
HEPES, (Gibco)) pre-filtered through cell separation magnet (BD Biosciences), and passed through a
magnetic column (Miltenyi Biotec). Rare T-cell subsets found in the spleen (Figure 3—figure supple-
ment 2) were enriched using a similar depletion protocol by labeling splenocytes with biotinylated
antibodies CD19, CD11b, CD11c, and Gr-1. Later-stage thymocyte precursors analyzed
(Figure 1D, Figure 3B, and Figure 3—figure supplements 1, 3, 4) or sorted (Figure 6A), and whole
splenocyte populations analyzed (Figure 3—figure supplements 2, 3) were directly stained with
conjugated fluorescent cell surface antibodies (see Supplementary file 1, Key Resources Table).
Bone Marrow (BM) cells were harvested from dissected femurs and tibiae of 2- to 3- month-old
Bcl11bYFP(neo)/mCh(neo) mice. Fetal livers (FLs) were removed from F0 chimeric fetuses of pregnant sur-
rogate mice at E14.5, individually disrupted mechanically via pipetting into whole organ suspension,
and frozen down in freezing media (50% FBS, 40% aMEM, 10% DMSO) for liquid nitrogen storage.
Prior to in vitro culture use, BM and thawed FL cell suspensions were blocked in 2.4G2 supernatant,
tagged with biotinylated antibody lineage markers specific to BM (CD19, CD11b, CD11c, NK1.1,
Ter119, CD3e, Gr-1, B220) or FL (CD19, F4/80, CD11c, NK1.1, Ter119, Gr-1), and depleted of biotin-
streptavidin-magnetically labeled mature lineage cells as described above. Eluted lineage depleted
(Lin-) bone marrow progenitors were either frozen down in freezing media for storage in liquid nitro-
gen or used directly for in vitro cell culture assays of T-cell development, while Lin- fetal liver progen-
itors were immediately cultured.
In vitro differentiation of T-cell progenitors
DN T-cell precursors used for in vitro studies were generated by culturing BM and FL stem and pro-
genitor cells on a OP9-DL1 stromal monolayer culture system (Schmitt and Zu´n˜iga-Pflu¨cker, 2002),
following previously detailed methods (Kueh et al., 2016) with adapted variations as described
below. To promote the DN T-cell development, purified or thawed Lin- progenitors were cultured
on OP9-DL1 stromal cell monolayers (Schmitt and Zu´n˜iga-Pflu¨cker, 2002) plated on tissue-culture
treated plates (Corning) using standard culture medium [80% aMEM (Gibco), 20% Fetal Bovine
Serum (Sigma-Aldrich), Pen-Strep-Glutamine (Gibco), 50 mM b-mercaptoethanol (Sigma)], grown at
37˚C in 5% CO2 conditions, and supplemented with cytokines. All in vitro T-cell generation cultures
of Bcl11b-YFP/mCh Lin- BM precursors were supplemented with 5 ng/mL Flt-3L (Peprotech) and 5
ng/mL IL-7 (Peprotech), and were sorted after 6 or seven total days of culture following transduction
with a retroviral vector expressing CFP 1 day prior (Figures 2, 4F and 5A, and Figure 2—figure sup-
plement 1, Figure 4—figure supplements 1–2). Lin- fetal liver precursors were cultured with 5 ng/
mL Flt-3L and 1 ng/mL IL-7 for the indicated number of days before analysis or sorting. For experi-
ments in which Bcl11b locus activation was compared in the presence and absence of Notch signals,
DN2 progenitors were cultured in parallel with OP9-DL1 stroma and with OP9-Control (without DL1
expression), respectively, as previously described (Kueh et al., 2016).
Sorted thymocytes (Figures 3D and 6A), BM-derived DN2 progenitors (Figure 5A), and FL-DN
progenitors (Figure 6B) were seeded manually onto 6000 OP9-DL1 or OP9-Control feeder cells per
well in 96-well plates, cultured in standard medium supplemented with 5 ng/mL Flt-3L and either 5
ng/mL IL-7 (BM) or 1 ng/mL IL-7 (Thymocytes and FL), and harvested for analysis after the indicated
number of days.
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Flow cytometry and cell sorting
Unless otherwise noted, flow cytometry analysis and fluorescent-activated cell sorting of all in vitro
and ex vivo lymphocytes were prepared using the procedures outlined. Briefly, cultured cells on tis-
sue culture plates and primary cells from lymphoid organs were prepared as single cell suspensions,
incubated in 2.4G2 Fc blocking solution, stained with respective surface cell markers as indicated
(see Supplementary file 1, Key Resources Table), resuspended in HBH, filtered through a 40 mm
nylon mesh, and analyzed using a benchtop MacsQuant VYB flow cytometer (Miltenyi Biotec,
Auburn, CA) or sorted with Sony Synergy Sorter (Sony Biotechnology, Inc, San Jose, CA). Both
instruments contain capabilities to detect mCherry fluorescence by 561 nm laser excitation. All anti-
bodies used in these experiments are standard, commercially available monoclonal reagents widely
established to characterize immune cell populations in the mouse; details are given in
Supplementary file 1. Acquired flow cytometry data were all analyzed with FlowJo software (Tree
Star).
Timelapse imaging
Timelapse imaging of live-cells was used to study Bcl11b gene expression dynamics in single cells
(Figures 2 and 4F, and Figure 2—figure supplement 1, Figure 4—figure supplements 1–2, and
Video 1). To prepare for multi-day imaging, PDMS micromesh arrays (250 mm hole diameter, Micro-
surfaces, AU) containing small microwells that prevent seeded cells from migrating out of a single
imaging field of view on 40x objective were adhered to 24-well glass-bottomed plates (Mattek, Ash-
land, MA). To prevent overcrowding in microwells and enable proper cell tracking, non-GFP express-
ing OP9-DL1, described in Kueh et al., 2016, and sorted CFP+ DN2 progenitors were plated at
appropriate densities to achieve ~8 cells/microwell and ~1 cell/microwell, respectively. Cells were
cultured in standard medium using Phenol Red-free aMEM (Gibco) and supplemented with 5 ng/mL
Flt-3L and 5 ng/mL IL-7.
Image segmentation and analysis
Cells were segmented using image processing workflow implemented in MATLAB (Mathworks,
Natick, MA), as previously described in detail (Kueh et al., 2013; Kueh et al., 2016). Briefly, this
workflow involved: (1) Correction for uneven fluorescence illumination, calculated from a fluorescent
slide with uniform intensity, followed by background subtraction; (2) Automated cell segmentation,
using an Laplacian filter-based edge detection algorithm, followed by exclusion of non-cell objects
by size and shape selection. Cell segmentations were then subject to manual inspection, and seg-
mented objects that did not correspond to cells were then eliminated. For each data set, automated
segmentation parameters were chosen such that the fraction of incorrectly identified cells was <1%
of the total number of segmented cells. To calculate fluorescence intensities for segmented cells, we
first calculated average intensity levels for an annulus surrounding the segmented cell, and sub-
tracted this background value from image intensities in the cell interior. This additional subtraction
was performed to remove auto-fluorescence contributions from OP9-DL1 feeder cells to intensity
measurements. Fluorescence intensity measurements were either displayed for clonal cell lineages
confined within individual microwells (Figure 2B, C and Figure 2—figure supplement 1A, Fig-
ure 4—figure supplement 2B), or in a two-dimensional heat map showing the intensity distributions
for different indicated time windows for all 218 microwells in a single imaging experiment
(Figures 2B–D and 4F, and Figure 4—figure supplement 1).
To obtain the time evolution of Bcl11b population fractions, we fit the 2D histograms of Bcl11b-
YFP and Bcl11b-RFP levels, given by y and r respectively, to a sum of four 2D Gaussian functions:
F r;yð Þ ¼
X4
i¼1
fi r;yð Þ:
Each 2D Gaussian function is given by:
fi r;yð Þ ¼
Ni
2psr;isy;i
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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Here, we define the four populations i¼ 1 . . .4 to correspond to the non-expressing, yellow
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mono-allelic, red mono-allelic and bi-allelic populations respectively (Figure 4—figure supplement
1). Here, Ni corresponds to the volume under the Gaussian function when integrated over r and y.
When fitted to experimental 2D histogram, Ni provides an estimate of the number of cells within a
given population.
We performed our fitting in two steps: (1) we first obtained the means, standard deviations and
correlation coefficients of the Bcl11b non-expressing population r;1; y;1;sr;1;sy;1; 1
  
by fitting the
first 2D Gaussian function f1 r; yð Þ to a 2D histogram of Bcl11b-YFP and Bcl11b-RFP levels of cells at
the beginning of the experiment (within the time window 0<t<10 hr), which were sorted to have
both Bcl11b alleles inactive. This fit to the initial non-expressing Bcl11b population is crucial for accu-
rate determination of different Bcl11b allelic populations using the 4-Gaussian fit approach. (2) To
obtain a time series of Bcl11b allelic population fractions from single-cell data, we then fit the con-
strained 4-Gaussian model F r; yð Þ to 2D histograms of Bcl11b-YFP and RFP levels obtained across
successive time bins, fixing the parameters for the first Gaussian, and allowing the means, standard
deviations and correlation coefficients of the remaining Gaussians r;j; y;j;sr;j;sy;j; j
  
, j = 2. . ..4 to
vary within bounds set by the observed fluorescence distributions of the Bcl11b allelic-expressing
population. From these fits, we then obtain the observed fraction of cells in the ith state in a time
window centered on time t:
f obsi tð Þ ¼Ni tð Þ=
X4
j¼1
Nj tð Þ
To estimate confidence bounds, we also perform error analysis to get the confidence bounds
for fi tð Þ, given by:
df obsi ¼ f
obs
i
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
dNi
Ni
 2
þ
P4
j¼1
dN2j
P4
j¼1
Nj
 !2
vuuuuuuut
Here, dNi represents the error in the estimation of Ni from least squares fitting.
Model analysis and fitting
Models for Bcl11b activation (Cis-only, Sequential trans-cis, Parallele trans-cis; Figure 4A, Appendix)
were numerically simulated using an ordinary differential equation solver in MATLAB. The predicted
time course from these models were fit to experimental data, using a least-squares procedure with
the following free parameters: the cis- and trans- activation rates (kC and kT respectively), and the
fraction of cells in each Bcl11b non-expressing sub-state, constrained to equal one at t = 0 (sequen-
tial and parallel trans-cis models only). For both yellow/red mono-allelic and bi-allelic expressing
populations fractions, there is a clear lag in their rise kinetics of ~15–20 hr (Figure 4B), even though
all bi-allelic and mono-allelic expressing cells are all already discernible after the earliest measured
time interval (~5 hr, Figure 4—figure supplement 1, red arrows). This lag in measured population
fraction data occurs, because the earliest Bcl11b expressing cells still have fluorescent reporter levels
that are very similar to the non-expressing cell populations, and are therefore not detected by the
constrained Gaussian feature described above. Thus, to correct for this lag, we introduced detection
time delay into the fitting functions for the three Bcl11b –expressing populations, as follows:
f
0
i tð Þ ¼ fi t  tið Þ
Here, ti denotes the time delay in the detection of the ith allelic expression state, taken to be the
time at which the detected fraction of cells in the ith state increases to a value significantly greater
than zero. Note that as RFP and YFP differed in their accumulation rates and detection thresholds,
they showed different time delays for detection. We evaluated the goodness of each model fit by
calculating its reduced chi-squared value, defined as:
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2 ¼
P
i;j
fi;j f
obs
i;j
df obs
i;j
 
d:f:
where the summation is taken over all allelic expressing states i and all time points j, subject to the
time lag defined above, and the number of degrees freedom (d.f) is defined as the number of fitted
data points, minus the number of fitting parameters. To compare whether the sequential or parallel
trans-cis models provided a significantly better fit to the data compared to the cis- only model, we
then took the ratio of reduced chi-squared values for the two compared fits (i.e. their F values), and
evaluated for statistical difference using the F-test. Qualitative predictions for perturbing specific
reaction steps (Figure 5—figure supplement 1) were obtained by performing a series of simulations
with increasing magnitude of perturbation to the same ending time point. In accordance with experi-
mental observations showing some inactivation of the Bcl11b locus upon Notch withdrawal
(Figure 5A,B), perturbations involved both a reduction of the forward rate constant, and an increase
in the rate of a reverse reaction, together with a graded attenuation in the perturbation after activa-
tion of one Bcl11b allele (see Figure 5—figure supplement 1, and Appendix for a comprehensive
description). Parameters were chosen based on the best fits of the unperturbed time course
(Figure 4B), although the direction of the predicted shifts in phase space do not depend on the
exact parameters being chosen (Figure 5C,D, and Figure 5—figure supplement 1).
To generate predictions for allelic state distributions from single clones (Figure 4D,E), we per-
formed Monte-Carlo simulations of clonal single proliferating progenitor lineages, using Markov
transition probabilities determined by best-fit rate constants to sequential or parallel trans-cis mod-
els (see Appendix). Here, the cell division time was taken to be 20 hr, corresponding to rates of cell
expansion observed in experiments, and measurements of clonal allelic distributions were taken at
100 hr (i.e. after five cell divisions), also matching the time of experimental sampling. Probabilities
per cell division for each transition were obtained by converting the continuous-time models to a dis-
crete Markov chain, and these probabilities were taken to be independent between two daughters
of the same cell, consistent with the first-order kinetics of these transitions in our models. To test
experimental data against each model, we obtained the expected probability of having clones with
dual-allelic expression together with mono-allelic expression from two alleles (Y + R + D) or from a
single allele (Y + D and R + D) clones, for each model, and compared the observed frequencies from
clonal lineage data using a chi-squared test.
Radiation chimeras
Fetal liver precursor transplanted CD45.1 chimeras were generated to study the long-term T-cell
potential of cells without Bcl11b enhancer in mice. Individual fetal liver whole organ suspensions
were thawed and split for depletion protocols indicated above or stimulated in standard medium
supplemented with 50 ng/mL IL-6 (eBioscience), 50 ng/mL SCF (eBioscience), and 20 ng/mL IL-3
(eBioscience) for 2 days to enrich for hematopoietic stem cell (HSC) progenitors. CD45.1 C57BL/6
mice were subjected to sublethal radiation of 1000 rads from a cesium source. Cells were re-sus-
pended in PBS and 106 cells in a volume of 200 mL were injected retro-orbitally into anesthesized,
irradiated mice using 31G, 6 mm insulin syringes (BD). Comprehensive splenocyte analysis was per-
formed on 2-month post-transplantation chimeras by sacrificing mice and harvesting spleen and thy-
mus organs following protocols indicated above (Figure 3—figure supplement 3).
Retroviral transduction on Retronectin-DL1-coated plates
Retroviral particles were packaged by transient cotransfection of the Phoenix-Eco packaging cell line
with the retroviral construct and the pCL-Eco plasmid (Imgenex) using FuGENE 6 (Promega). Viral
supernatants were collected at 2 and 3 days after transfection and immediately frozen at  80˚C until
use. To infect BM-derived T-cell progenitors, 33 mg/mL retronectin (Clontech) and 2.67 mg/mL of
DL1-extracellular domain fused to human IgG1 Fc protein (Varnum-Finney et al., 2000) were added
in a volume of 500 mL per well in 24-well tissue culture plates (Costar, Corning) and incubated over-
night. Viral supernatants were added next day into coated wells and spun down at 2000 rcf for 2 hr
at room temperature. BM-derived T-cell progenitors used for viral transduction were cultured for 5
days according to conditions described above, disaggregated, filtered through a 40 mm nylon mesh,
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and 106 cells transferred onto each retronectin/DL1-coated virus-bound 24-well supplemented with
5 ng/mL SCF (Peprotech), 5 ng/mL Flt3-L, and 5 ng/mL IL-7.
Quantification and statistical analysis
The sample size for each experiment, and number of independent experiments are stated in the Fig-
ures and Figure Legends. In Figure 4B, the best fits of the different models were evaluated by com-
paring sum-squared errors using the F-test (Figure 4C), adjusted for different degrees of freedom
for each model. A chi-squared test was applied to compare experimental data against model predic-
tions shown in Figure 4F. Data that had a calculated p-value<0.05 was considered statistical signifi-
cant, and exact P-values are reported in the figure legends. Bar chart data shown (Figure 6A,B)
represent mean and standard deviation.
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Introduction
We describe a series of dynamical models that aim to clarify the interplay between global
(trans) and locus-specific (cis) mechanisms in the control of Bcl11b activation and T-lineage
commitment. We first use these models to understand the dynamics of normal Bc11b
activation in an initial population of DN2 progenitors that are inactive for both Bcl11b copies
(Figure 4). Next, to distinguish between these different models, we will make predictions
about their behavior on a clonal lineage level (Figure 4D–E), and their responses to
perturbations of different activation steps (Figure 5C-D and Figure 4—figure supplement 2,
Figure 5—figure supplement 1), which we will test experimentally. In these models, we do
not explicitly model the ETP to DN2 transition, as our experiments all start with cells that have
already turned on CD25; however, as we discuss below, our analysis of the sequential and
parallel trans-cis models suggest that some of the molecular events we consider could occur
prior to the ETP-DN2 transition. We note that these models are simplified representations of
more complex underlying systems, and a full understanding of the dynamics of the complete
system will involve additional processes not accounted for here. However, we use these
minimal models to constrain experimental data, evaluate the plausibility of broad classes of
mechanisms, and provide a starting point for further investigation.
Simple cis-activation model
In this model, activation of Bcl11b involves a single, slow first-order step that takes place in cis,
that is on the locus of the Bcl11b gene itself. This activation step is controlled independently
for two copies of Bcl11b in a single cell, and with the same rate constant. Under these
assumptions, the fraction of non-expressing, mono-allelic and bi-allelic Bcl11b expressing cells
evolve over time according to the following dynamical equations:
dn0
dt
¼ 2kC  n0 (1)
dny
dt
¼ kC n0  ny
  
dnr
dt
¼ kC n0  nrð Þ
dnyr
dt
¼ kC nrþ ny
  
Here kC is the first-order rate constant of the slow cis-acting step on the Bcl11b locus. In
our experiments, starting DN2 progenitors were sorted to have no Bcl11b expression on
either copy. Thus, in our model fitting, we take all starting cells to be in a non-expressing
state, following this initial condition:
n0 0ð Þ ¼ 1 (2)
Accordingly, all other variables are set to zero. Following this initial condition, we
performed least-squares fitting, varying kc to provide the best fit to experimental data
(Figure 4B). We note that in this and subsequent fits, experimental data were shifted by a
fixed time lag, to account for delays in the appearance of fluorescent protein expression.
As seen from best least-squares fit, this model is a poor description of the experimentally
observed dynamics of Bcl11b activation from DN2 (Figure 4B–C): this is because the fraction
of bi-allelic expressing cells increases more slowly compared to that of the mono-allelic
expressing cells at the earliest time points. To see how this this time lag arises, we can solve
for this model analytically, to derive the following solutions:
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n0 tð Þ ¼ e
 2t (3)
ny tð Þ ¼ e
 t  e 2t
nr tð Þ ¼ e
 t  e 2t
nyr tð Þ ¼ 1þ e
 2t  2  e t (4)
Where t ¼ kCt is time in non-dimensional units. At early time points, where t 1, we can
expand these solutions using a power series to obtain:
ny »t (5)
nyr »t
2 »n2y (6)
At early time points, the fraction of bi-allelic expressing cells is approximately the square of
fraction of the mono-allelic expressing cells, and would therefore increase at a slower rate
relative to mono-allelic expressing cells.
Sequential trans-cis activation model
In this model, two rate-limiting steps are required for activation of Bcl11b, a trans-acting step,
which occurs in the nucleus away from the Bcl11b locus, and a cis-acting step, which occurs
independently on each Bcl11b locus. The trans step precedes, and is necessary for, the cis
step. Such a model could describe a reaction scheme, where an initial limiting step, occurring
away from the Bcl11b locus, activates a regulatory factor that facilitates the cis- activation step
in a permissive fashion. This regulatory factor could be a chromatin-modifying enzyme, a
transcription factor, or any other protein that serves to enable locus remodeling. We note that
in this model, it is possible that the trans-acting step occurs before the DN2 transition
(Figure 4A, gray arrows).
There are five states, a trans-inactive state M0, where this trans factor is absent, and four
states, N0, Ny, Nr, and Nry, where the trans factor is present, and two copies of Bcl11b exist in
either active or inactive states. The time evolution of the fraction of DN2 progenitors in these
different states are given by:
dm0
dt
¼ kTm0 (7)
dn0
dt
¼ kTm0  2kCn0
dny
dt
¼ kC n0  ny
  
dnr
dt
¼ kC n0  nrð Þ
dnyr
dt
¼ kC nr þ ny
  
Here, kT and kC correspond to the first-order rate constants for the trans and cis-acting
steps respectively. The value of these rate constants were determined using least-squares
fitting to experimental data, subject to the constraint that the initial DN2 progenitors that we
sorted are all inactive for both copies of Bcl11b, and must exist in either trans-active or trans-
inactive states:
m0 0ð Þþ n0 0ð Þ ¼ 1: (8)
This constraint results in one additional fitting parameter to the model. The best fit
trajectory is shown in the main text (Figure 4B), and best-fit parameters are shown in
Appendix 1—table 1. Unlike the simple cis-activation model, this model can give rise to a rise
in the fraction of bi-allelic expressing fraction concurrent with the mono-allelic expressing
fraction (Figure 4B–C); thus, from least-squares fitting of experimental data alone, the
sequential activation model can plausibly explain experimentally observed population
dynamics.
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Appendix 1—table 1. Best fit parameters of the sequential trans-cis activation model to data,
with 95% confidence intervals.
Parameter Units Best-fit Lower bound Upper bound
kc 1/hr 3:5 10
 2
3:3 10 2 3:6 10 2
kt 1/hr 3:3 10
 2
3:1 10 2 3:6 10 2
m0 I 0:81 0:78 0:83
DOI: https://doi.org/10.7554/eLife.37851.029
Parallel trans-cis-activation model
In this model, cis-acting and trans-acting steps are also required for activation of Bcl11b,
similar to the sequential activation model. However, in contrast to the sequential model, cis
and trans steps occur in parallel with each other, such that they occur in either order. In this
model, the trans step could represent activation of a trans factor necessary for transcription
of a cis-activated locus. For instance, the trans-acting step could correspond to the activation
of a factor that promotes the polymerase recruitment.
In this model, there are four trans-inactive states M and four trans-active states N, each
corresponding to different states of locus activation. The time evolution of the fraction of
cells in these states are given by:
dm0
dt
¼ 2kCm0 (9)
dmy
dt
¼ kCm0 ðkT þ kCÞmy
dmr
dt
¼ kCm0 ðkT þ kCÞmr
dmyr
dt
¼ kCðmrþmyÞ  kTmry
dn0
dt
¼ kTm0  2kCn0
dny
dt
¼ kCn0þ kTmy  kCny
dnr
dt
¼ kCn0þ kTmr   kCnr
dnyr
dt
¼ kCðnrþ nyÞþ kTmry
Here, kT and kC correspond to the first-order rate constants for the trans- and cis- acting
steps. As experiments start with cells that do not express Bcl11b, the following constraint
describes the fitting of our models:
m0 0ð Þþmy 0ð Þþmr 0ð Þþmry 0ð Þþ n0 0ð Þ ¼ 1 (10)
This constraint results in four additional free parameters to the least-squares fit. Upon
performing a least-square fit to experimental data, we find that this model also recapitulates
the early rise in the fraction of bi-allelic expressing cells, as observed in the data (Figure 4B–
C; see Appendix 1—table 2 for best-fit parameter values). Of note, our model fit suggests
that a significant fraction of DN2 progenitors may already exist in a state where one or both
Bcl11b alleles are already activated in cis (Appendix 1—table 2). This feature of our fit will
enable us to distinguish between the sequential and parallel activation models using clonal
lineage data, as we discuss further below.
Appendix 1—table 2 Best fit parameters of the parallel trans-cis activation model to data,
with 95% confidence intervals.
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Parameter Units Best-fit Lower bound Upper bound
kc 1/hr 5:2 10
 3
4:3 10 3 6:2 10 3
kt 1/hr 2:7 10
 2
2:6 10 2 2:8 10 2
m0 (fraction) 0:21 0:14 0:33
mr , my (fraction) 0:29 0:27 0:31
mry (fraction) 0:21 0:20 0:23
DOI: https://doi.org/10.7554/eLife.37851.030
Comparative analysis of sequential and parallel trans-cis activation
models
Clonal heterogeneity analysis
So far, both sequential and parallel trans-cis activation models provide a reasonable fit to the
population dynamics of mono-allelic and bi-allelic cell fractions starting from non-expressing
progenitors (Figure 4B–C). How can we further distinguish between these two models? So
far, we have only considered predictions based on the behavior of whole cell populations;
however, analysis of correlations within individual lineage trees can allow discrimination of
distinct dynamic mechanisms, as was demonstrated in recent work and in classic experiments
(Luria and Delbru¨ck, 1943; Hormoz et al., 2016; Blanpain and Simons, 2013). As these
two models differ in activation state trajectories taken during Bcl11b activation, they would
be expected to generate distinct distributions of allelic activation states in single clonal
lineages.
To derive Bcl11b activation state distributions expected from either sequential or parallel
activation models, we first reformulate these models (Equations 7 and 9) as discrete time
Markov Chains (Gardiner, 2009), where each time step represents a single cell cycle. First,
let N be the total number of states. Next, define a random state variable St, corresponding
to the state of the cell at the number t. For the sequential model (Equation 7), the list of
states is m0; n0; ny; nr; nyr
 	
, with N ¼ 5; for the parallel model (Equation 9), the list of states is
m0;my;mr;myr; n0; ny; nr; nyr
 	
, with N ¼ 8. In our descriptions below, we will enumerate all the
states as i ¼ 1:::N in such a specified order.
Next, we define T, a transition matrix with N  N elements, where Tij represents the
probability of a cell transitioning from state j to state i in a single cell cycle. For a given cell
cycle time tc, we can solve the differential equations in Equations 7 and 9 to obtain
corresponding transition probabilities, that is Tij tcð Þ. In our simulations, we first solve for
these transition probabilities, using the best-fit rate constants in Appendix 1—table 1 and
Appendix 1—table 2. These experiments also used a cell cycle time of tc ¼ 20 hr. This was
chosen in accordance with the amount of cell expansion observed in imaging experiments,
though our conclusions are not expected to depend on the exact value of the cell division
time. With this transition probability matrix, we can then simulate state transitions across a
lineage of dividing cells, according to the following formula:
Pr Stþ1 ¼ ijSt ¼ jð Þ ¼ Tij (11)
Here St represents the state of the cell at the (t) th cell cycle. In the Monte-Carlo
simulations, each cell gives rise to two cells at each cell division, and each daughter cell
chooses its fate randomly and independently from its sibling, based on this formula. This
process is repeated iteratively for every descendant from a single ancestor until a designated
stopping time (5 cell cycles, or 100 hr, corresponding to the end of the imaging experiment),
whereby a complete lineage tree is generated.
From these clonal lineage simulations, we find the sequential and parallel trans-cis
activation models yield divergent predictions of heterogeneity in Bcl11b allelic activation at
the level of single clones. For the sequential activation model, non-expressing ancestors
predominantly generate a mixture of progeny with mono-allelic expression from both Bcl11b
copies prior to bi-allelic Bcl11b activation (Figure 4D–E). While some clones only express a
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single specific Bcl11b copy prior to bi-allelic activation, these clones were rare relative to
those with mono-allelic expression from each of the two alleles (Figure 4D). This is because
all non-expressing progenitors still have both Bcl11b copies in a cis-inactive state; thus, upon
cell division, all daughters of a non-expressing parent retain the same probability of
activating either allele.
By contrast, the parallel trans-cis activation model gave rise to a large frequency of clones
with mono-allelic expression from only one specific allele (Figure 4D–E), either red or yellow,
varying between, but not within, different clones. This reflects the accumulation of non-
expressing progenitors that have a single Bcl11b copy present in an open state, but lack the
trans-acting factors necessary to induce expression from this opened locus (58% total,
Appendix 1—table 2). These clones pass through a single specific mono-allelic activation
intermediate prior to bi-allelic activation. Additionally, in the parallel activation model, a
small percentage of clones transition directly to a bi-allelic expressing state without first
passing through a mono-allelic state (Figure 4D–E), a behavior that does not occur for the
sequential activation model. This ‘tunneling’ of non-expressing cells to a bi-allelic expression
state reflects the existence of non-expressing cells with both alleles open that still lack the
critical trans-acting step to enable their expression. For these cells, activation of the trans-
acting step causes both alleles to turn on simultaneously.
In our experimentally observed distributions of allelic activation states, we found that
individual clones predominantly showed mono-allelic expression from only one allele
(Figure 4F, 7/9 clones observed), but only rarely showed mono-allelic expression of both
alleles (Figure 4F, 1/9 clones observed). This distribution of single-specific mono-allelic
clones was significantly different from the fractions predicted for the sequential activation
model (p<0:01, 2 = 6.8, d.f. = 1), but not significantly different from predictions for the
parallel activation model.
Furthermore, the experimentally observed distributions also showed evidence for
simultaneous activation of both alleles from a non-expressing state (Figure 4E, 1/9 clones),
consistent with the occurrence of a parallel trans-activation event in a DN2 progenitor with
both Bcl11b alleles pre-activated in cis, which is only allowed in the parallel activation model.
Taken together, the experimental clonal lineage data favor the parallel activation model as
an explanation for the underlying kinetic processes controlling Bcl11b activation, suggesting
that the trans- acting step necessary for Bcl11b activation occurs in parallel with the cis-level
step on the Bcl11b locus.
Effects of perturbation of cis and trans activation steps
To further discriminate between sequential and parallel trans-cis activation events, and to
gain insights into the molecular mechanisms underlying control of the trans-acting step, we
analyzed the predicted effects of perturbing different reaction steps for each model. We
then tested these predictions by removing the Notch signaling ligand DL1, an essential T-cell
developmental signal that controls Bcl11b activation probabilities. Here, we show that
perturbations of the reaction steps in different models generate distinct shifts in the
distribution of mono-allelic and bi-allelic expressing cells, which can be compared to
experiments for model discrimination. In this simulation analysis (Figures 5C-D and
Figure 5—figure supplement 1), we perturbed both cis- and trans-acting steps in the two
models in the same way, by reducing its forward rate while introducing a non-zero backward
rate. This assumption of reversibility reflects our previous observations that Bcl11b can turn
back off in a small fraction of cells. We previously noted that although Bcl11b expression
maintenance rapidly becomes Notch-independent, there is a small percentage of cells that
can lose Bcl11b expression again shortly after activation, if Notch signaling is removed
(Kueh et al., 2016). Thus, building on this observation, we reduced the forward rate constant
by a fraction d, while concomitantly increasing the back rate constant by the same amount d.
Also, in accordance with experimental observations (We attenuated Notch-dependency as
described because experiments showed that cells with both Bcl11b alleles active show a
reduced rate of reversion to an inactive state upon Notch signaling withdrawal. The
molecular basis for this attenuation in Notch dependency is currently unclear, but likely
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involves involve a parallel process occurring in the nuclei of progenitors to stabilize a Notch-
driven T-lineage program over time.), the effect of each perturbation on the change in rate
constants was further reduced a multiplicative factor f <1ð Þ for transitions to and from a dual-
allele expressing state. The perturbed rate constants are labeled in the state transition
diagrams in Figure 5—figure supplement 1, and their definitions, as described here, as
listed in Appendix 1—tables 3–6. We note that, while the magnitudes of the experimentally
observed shifts depend on these chosen values, the directions of these shifts in phase space
upon perturbation - corresponding to the increases or decreases in ratio of bi-allelic to
mono-allelic expressing cells - are not dependent on the specific values of chosen constants,
and thus represents a robust qualitative prediction of the modeling.
By numerically simulating these models, we found that different perturbations generated
distinct shifts in Bcl11b mono-allelic to bi-allelic ratios that could then be used to distinguish
between effects of Notch on the cis versus trans steps. Specifically:
. When cis-acting steps are perturbed in both the sequential and parallel activation models,
non-expressing or mono-allelic expressing starting progenitors reach a final state with
reduced bi-allelic expression, and either reduced (sequential activation model) or increased
(parallel activation model) mono-allelic expression (Figures 5C and Figure 5—figure sup-
plement 1, blue arrows). However, the ratio of bi-allelic to mono-allelic expressing cells
Fb=Fmð Þ invariably decreases, such that the line connecting initial to final states in phase
space makes a smaller angle with the x-axis when perturbation is applied. This result does
not depend on the exact perturbation strengths specified by d, and also does not depend
on whether perturbations are reduced for transitions involving the bi-allelic state (f<1), or
whether they remain the same (f ¼ 1) (See Figure 5—figure supplement 1).
. When the trans-acting step in the sequential activation model is perturbed, progenitors
starting without Bcl11b expression (Figure 5—figure supplement 1, sequential model)
reach a final state with a reduced fraction of mono-allelic and bi-allelic expressing cells. Pro-
genitors starting with mono or bi-allelic expression are not affected (Figure 5—figure sup-
plement 1, sequential model).
. When the trans-acting step in the parallel activation model is perturbed, non-expressing
and mono-allelic progenitors reach a final state with reduced mono-allelic and bi-allelic
expression, but also show a decrease in the ratio of mono-allelic to bi-allelic expressing cells
(Figure 5D). As explained above, this increase in Fb=Fm cannot occur with inhibition of the
cis-acting step in either the sequential or parallel model, and cannot occur when starting
with mono-allelic expressing cells in the sequential activation model. Hence, this shift distin-
guishes the parallel from the sequential activation model. Here, we note that bi-allelic cells
show a proportionately smaller decrease relative to mono-allelic cells, because transitions
involving this state are impacted less by the perturbation (f<1). If all transition rates were
affected uniformly (f ¼ 1), both mono-allelic and bi-allelic cells would be affected similarly,
such that the ratio of the two populations would remain the same (Figure 5—figure supple-
ment 1).
. Furthermore, when starting from a bi-allelic expressing state, perturbation of the trans step
causes direct transition to a non-expressing state, without passage through a mono-allelic
expressing intermediate (Figure 5—figure supplement 1, parallel model). This bi-allelic
inactivation represents the reversion of the progenitor to a state where cells still maintain
two cis-active Bcl11b alleles cis, but have now inactivated a parallel trans-acting step neces-
sary for expression from a cis-opened locus. As this bi-allelic shutoff would not be predicted
to happen upon perturbation of any other step in either model, it provides an additional
signature of the parallel activation model.
Taken together, this analysis suggests that the sequential and parallel activation models
could potentially be distinguished by analyzing changes in the fractions of non-expressing,
mono-allelic, and bi-allelic cells in response to perturbation, if this perturbation involved a
disruption of the trans-acting step for Bcl11b expression.
To test these predictions, we sorted DN2 progenitors with different numbers of active
Bcl11b alleles, cultured them in vitro in either the presence (unperturbed condition) or
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absence (perturbed condition) of Notch signaling, and then analyzed allelic activation states
after four days using flow cytometry.
Consistent with parallel activation model, Notch withdrawal reduced the proportion of
mono-allelic to bi-allelic expression in cells that started with zero or one active copies of
Bcl11b (Figure 5A–B). It also caused the direct transition of bi-allelic expressing cells to a
non-expressing state, without passing through a mono-allelic intermediate state, as can be
seen in the flow cytometry analysis of the effects of Notch removal on progenitors
expressing both copies of Bcl11b (Figure 5A, green arrow). These experiments reveal a
strong correlation at the single-cell level between expression levels of Bcl11b-YFP and
Bcl11b-mCherry alleles, in cells that are shutting off their expression, suggesting that the
inactivation of Bcl11b upon Notch withdrawal occurred in a highly synchronous manner for
two alleles.
Taken together, our results support the parallel activation model over sequential
activation model, and indicate that Notch signaling effectively represents one parallel trans-
acting step necessary for Bcl11b expression.
Appendix 1—table 3. Perturbing the cis-acting step in the sequential activation model.
Parameter Description
k0f ¼ kC 1  dð Þ cis-activation rate, from non-expressing to mono-allelic state
k1f ¼ kC 1  f  dð Þ cis-activation rate, from mono-allelic to bi-allelic state
k0r ¼ kC  d back cis-activation rate, from mono-allelic to non-expressing state
k1r ¼ kC  f  d back cis-activation rate, from bi-allelic to mono-allelic state
kT trans-activation rate
d 0 to 0.35
f 0.4
DOI: https://doi.org/10.7554/eLife.37851.031
Appendix 1—table 4. Perturbing the trans-acting step in the sequential activation model.
Parameter Description
kC cis-activation rate
k0f ¼ kT 1  dð Þ trans-activation rate
k0r ¼ kT  d back trans-activation rate
d 0 to 0.35
DOI: https://doi.org/10.7554/eLife.37851.032
Appendix 1—table 5. Perturbing the cis-acting step in the parallel activation model.
Parameter Description
k0f ¼ kC 1  dð Þ cis-activation rate, from non-expressing to mono-allelic state
k1f ¼ kC 1  f  dð Þ cis-activation rate, from mono-allelic to bi-allelic state
k0r ¼ kC  d back cis-activation rate, from mono-allelic to non-expressing state
k1r ¼ kC  f  d back cis-activation rate, from bi-allelic to mono-allelic state
kT trans-activation rate
d 0 to 0.35
f 0.4
DOI: https://doi.org/10.7554/eLife.37851.033
Appendix 1—table 6. Perturbing the trans-acting step in the parallel activation model.
Parameter Description
Appendix 1—table 6 continued on next page
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Appendix 1—table 6 continued
Parameter Description
kc cis-activation rate
k0f ¼ kT 1  dð Þ trans-activation rate, from non-expressing/mono-allelic state
k1f ¼ kT 1  f  dð Þ trans-activation rate, from bi-allelic state
k0r ¼ kT  d back trans-activation rate, from non-expressing/mono-allelic state
k1r ¼ kT  f  d back trans-activation rate, from bi-allelic state
d 0 to 0.65
f 0.2
DOI: https://doi.org/10.7554/eLife.37851.034
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